

1 *Bifidobacterium longum* modifies a nutritional intervention for stunting in Zimbabwean infants

2 Authors: Ethan K Gough^{1,*}, Thaddeus J Edens², Lynnea Carr³, Ruairi C Robertson⁴, Kuda Mutasa⁵, Robert
3 Ntozini⁵, Bernard Chasekwa⁵, Hyun Min Geum⁶, Iman Baharmand⁶, Sandeep K Gill⁶, Batsirai Mutasa⁵,
4 Mduduzi N N Mbuya^{5,7}, Florence D Majo⁵, Naume Tavengwa⁵, Freddy Francis⁸, Joice Tome⁵, Ceri Evans⁴,
5 Margaret Kosek⁹, Jean H Humphrey^{1,5}, Andrew J Prendergast^{4,5}, Ameer R Manges^{6,10} for the Sanitation
6 Hygiene Infant Nutrition Efficacy (SHINE) Trial Team.

7 Affiliations:

- 8 1. Department of International Health, Johns Hopkins Bloomberg School of Public Health,
9 Baltimore, MD, 21205, USA.
- 10 2. Devil's Staircase Consulting, West Vancouver, BC, Canada.
- 11 3. Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC,
12 V6T 1Z3, Canada.
- 13 4. Blizard Institute, Queen Mary University of London, London, E1 2AT, UK.
- 14 5. Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe.
- 15 6. School of Population and Public Health, University of British Columbia, Vancouver, BC, V6T 1Z3,
16 Canada.
- 17 7. Global Alliance for Improved Nutrition, Washington, DC, 20036, USA.
- 18 8. Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V6T 1Z2,
19 Canada.
- 20 9. University of Virginia, School of Medicine, Charlottesville, VA, USA.
- 21 10. British Columbia Centre for Disease Control (BCCDC), Vancouver, BC, Canada.

22 *Correspondence: egough1@jh.edu

23

24 **Summary (word limit: 150)**

25 Child stunting is an indicator of chronic undernutrition and reduced human capital. However, it remains
26 a poorly understood public health problem. Small-quantity lipid-based nutrient supplements (SQ-LNS)
27 have been widely tested to reduce stunting, but have modest effects. The infant intestinal microbiome
28 may contribute to stunting, and is partly shaped by mother and infant histo-blood group antigens
29 (HBGA). We investigated whether mother-infant fucosyltransferase status, which governs HBGA, and
30 the infant gut microbiome modified the impact of SQ-LNS on stunting at age 18 months among
31 Zimbabwean infants in the SHINE Trial (NCT01824940). We found that mother-infant fucosyltransferase
32 discordance and *Bifidobacterium longum* reduced SQ-LNS efficacy. Infant age-related microbiome shifts
33 in *B. longum* subspecies dominance from *infantis*, a proficient human milk oligosaccharide utilizer, to
34 *suis* or *longum*, proficient plant-polysaccharide utilizers, were partly influenced by discordance in
35 mother-infant FUT2+/FUT3- phenotype, suggesting that a “younger” microbiome at initiation of SQ-LNS
36 reduces its benefits on stunting.

37

38 Keywords: microbiome, nutrition, fucosyltransferase, histo-blood group antigen, stunting, infant

39

40

41

42

43

44

45 Introduction

46 Globally, 21% of children under 5 years of age (149 million) are stunted¹, defined as having a length
47 or height >2 standard deviations below an age- and sex-matched reference population median². Deficits
48 in linear growth largely accrue from conception to 24 months of age^{3,4}, corresponding to the period
49 when normal child growth and development is most rapid. Stunting is associated with reductions in child
50 survival, neurodevelopment, educational attainment, and adult economic productivity⁵⁻⁷.

51 A broadly tested intervention to reduce stunting has been provision of small-quantity lipid-based
52 nutrient supplements (SQ-LNS) to improve infant and young child feeding (IYCF) starting at 6-months
53 (mo) of age, which is the recommended time for introduction of complementary foods. Randomized
54 controlled trials (RCT) of SQ-LNS provision to infants have shown small reductions in stunting (12%
55 relative reduction), but effects have varied^{8,9}. Evidence to support other nutrition interventions, which
56 address the underlying determinants of stunting during the first 1000 days of life, starting from
57 conception, is also limited¹⁰. Elucidating the reasons for the limited impact of nutritional interventions
58 that are designed to alleviate stunting is crucial to the development of more effective strategies.

59 Recently, the human microbiome has been shown to impact infant health¹¹, and studies suggest a
60 role of the intestinal microbiome in child growth, particularly ponderal growth^{12,13}. The prevailing view
61 holds that intestinal colonization with bacteria begins at birth, after which the microbiome progresses
62 through a succession of identifiable shifts in composition and functional capacity¹¹ that correspond
63 closely with infant age and developmental stage¹⁴. Deviations from an age-appropriate composition may
64 be associated with poor health outcomes¹⁴⁻¹⁷, including undernutrition in low resource settings^{14,18-20}.
65 However, results vary²¹⁻²⁵ and evidence for a causal effect of the intestinal microbiome on growth
66 comes predominantly from animal models. In these experiments, a combination of commensal bacteria
67 and a nutrient-poor diet produce a synergistic effect on growth faltering. The detrimental effect on
68 growth was worse when certain commensal bacteria, which can act as opportunistic pathogens (e.g.

69 *Bacteroides thetaiotaomicron* and *Bacteroides fragilis*), were present in the gut along with pathogenic
70 species^{26,27}.

71 The gut microbiome in infants is influenced by breastfeeding, with differences persisting beyond age
72 6mo¹⁶. Breastfeeding-associated differences are partly driven by differences in human milk
73 oligosaccharide (HMO) composition, which are metabolized by specific commensal bacteria and thereby
74 influence the growth and activity of specific bacterial populations in the infant gut, in particular,
75 *Bifidobacterium*^{28,29}. In addition, HMOs in combination with commensal gut bacteria have been shown
76 to improve growth in animal models of undernutrition³⁰. Active maternal α -1,2-fucosyltransferase
77 (FUT2) and α -1,3-fucosyltransferase (FUT3) genes are key determinants of HMO composition³¹⁻³³. These
78 genes encode enzymes which catalyze addition of fucose to the disaccharides that serve as precursors to
79 host glycan production^{34,35}. Individuals with at least one functional FUT2 or FUT3 allele produce
80 fucosylated histo-blood group antigens (HBGA) and are called “secretors” or “Lewis-positive”,
81 respectively;³⁵ by contrast, individuals lacking two functional FUT2 or FUT3 alleles don’t produce
82 fucosylated HBGAs, and are termed “non-secretors” or “Lewis-null”, respectively³⁵. These secretor and
83 Lewis phenotypes act in concert to synthesize a variety of HBGAs (Figure S1)^{34,35}. In addition to the
84 impact of maternal FUT2 or FUT3 status on the infant gut microbiome via their influence on HMO
85 composition, host FUT2 and FUT3 phenotypes also determine tissue surface HBGA expression in the gut,
86 which may also affect the microbiome through the availability host glycans and competition for
87 adhesion sites³⁶⁻⁴⁰.

88 There is growing interest in the moderating effect of the gut microbiome on nutritional
89 interventions. Recent RCTs showed that the impact of dietary interventions for weight-reduction on
90 metabolic health outcomes is modified up to 4-fold by microbiota composition⁴¹⁻⁴⁴. Effect modification
91 of host diet by the gut microbiota has also been investigated in observational studies, which report that
92 microbiome composition modified the association between diet and biomarkers of metabolic syndrome

93 by up to 2-fold⁴⁵⁻⁴⁷. Gut microbiota composition, therefore, may also be an important modifier of dietary
94 interventions on infant health. Only one study to date investigated the gut microbiota as an effect
95 modifier of SQ-LNS on infant stunting, and reported limited evidence of effect-modification⁴⁸. However,
96 several studies have reported a synergistic effect of microbiome composition and diet on undernutrition
97 phenotypes using animal models^{26,27,49,50}.

98 Here we aimed to determine the effect of infant gut microbiome composition and functional
99 capacity on efficacy of an IYCF intervention that included SQ-LNS to reduce stunting (primary outcome)
100 and improve length-for-age z-score (LAZ) (secondary outcome) at age 18mo. We hypothesized that the
101 efficacy of IYCF, when started at age 6mo, on infant linear growth is modified by mother and infant FUT2
102 and FUT3 phenotype, as an early driver of variation in gut microbiome composition, and by the infant
103 gut microbiome. We tested this hypothesis using data from HIV-unexposed infants enrolled in the
104 Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial conducted in rural Zimbabwe, in which the IYCF
105 intervention modestly increased LAZ by 0.16 standard deviations and reduced stunting by 20% at age
106 18mo⁵¹. We found that mother-infant FUT2 and FUT3 phenotype was associated with reduced IYCF
107 impact on stunting at 18mo. Reduced impact of IYCF on stunting was also associated with age-related
108 changes in infant microbiome species composition, characterized by a shift away from *Bifidobacterium*
109 *longum* carriage. *B. longum*-dominant microbiome composition was characterized by *B. longum* strains
110 that were most similar to subspecies *infantis*, a proficient HMO utilizer. In addition, *B. longum*
111 abundance and odds of detecting different *B. longum* strains were explained by infant age and mother-
112 infant FUT2 and FUT3 phenotype.

113

114

115

116

117 **Results**

118 *Mother-infant FUT2+/FUT3- phenotype discordance modifies the effect of IYCF on stunting at 18mo*

119 In a substudy of the SHINE trial, we assessed FUT2 and FUT3 status in mothers and infants from
120 saliva samples⁵⁴. In order to determine the impact of maternal and infant HBGA on IYCF efficacy, we
121 investigated whether concordance in secretor (FUT2) and Lewis (FUT3) phenotypes between mother
122 and infant pairs modified the effect of IYCF on stunting or LAZ at 18mo. We also used combinations of
123 FUT2 and FUT3 status (Table S1) in order to more precisely reflect the potential for joint activity of these
124 enzymes in HBGA production on linear growth (Figure S1). Paired mother-infant FUT2/FUT3 phenotypes
125 were classified as *both* (if mother and infant shared the same phenotype), *none* (if neither had the
126 phenotype), *infant only* (if the infant had the phenotype but the mother did not) or *mother only* (if the
127 infant did not have the phenotype but the mother did). We fitted multivariable regression models that
128 included interaction terms for IYCF-by-paired mother-infant FUT2/FUT3 phenotype combinations, as
129 well as prespecified covariates from the 6mo follow-up visit when IYCF was started, with stunting status
130 at the 18mo visit as the dependent variable. We fitted separate models for each FUT2/FUT3 phenotype
131 combination (Table S1, Figure S1). These models were restricted to 792 infants who had both maternal
132 and infant FUT2 and FUT3 status ascertained (Figure S2). Analyses were repeated with LAZ at the 18mo
133 visit as the dependent variable.

134 Amongst infants who were randomized to IYCF, those who were in the *mother only* FUT2+/FUT3-
135 group (13.5%), had a probability of stunting at 18mo that was -33.0% lower (95%CI:-55.0%,-10.0%) than
136 infants in the *both* FUT2+/FUT3- group (11.1%) (Table 1). The *infant only* (11.1%) and *none* (64.3%)
137 FUT2+/FUT3- groups and other mother-infant FUT2 and FUT3 phenotype combinations (Table S1, Figure
138 S1) did not show evidence of effect modification of IYCF on stunting (Table S2), and there was no
139 evidence of effect modification on LAZ at 18mo after FDR-adjustment for multiple testing (Table S3).
140 Overall, our results indicate that discordance between mothers and infants in the FUT2+/FUT3-

141 phenotype, whereby mothers had the phenotype and infants didn't have the phenotype, was associated
142 with increased efficacy of IYCF to reduce stunting but not to increase LAZ.

143

144 *Infant gut microbiome composition modifies the effect of the IYCF intervention on stunting at 18mo*

145 Given our finding that infants whose mothers were FUT2+/FUT3-, while the infant was not, had
146 greater reductions in stunting by IYCF; and considering the potential importance of FUT2/FUT3
147 phenotypes on early infant microbiome composition via variation in maternal HMO composition and
148 infant gut epithelial HBGA expression, we investigated whether infant gut microbiota species turnover
149 showed evidence for modification of IYCF efficacy on stunting or LAZ at 18mo. First, we used 354 infant
150 metagenomes from 172 infants collected from 1-18mo of age to fit a constrained Principal Coordinates
151 Analysis (PCoA) model that included infant age at stool collection and three dummy variables for
152 mother-infant FUT2+/FUT3- status representing the *none*, *infant only*, and *mother only* groups with the
153 *both* group as the referent (see next section for details). Thus, we derived four PCoA axis scores from
154 this model representing variation in microbiome composition due to infant age and *none*, *infant only*, or
155 *mother only* FUT2+/FUT3- status compared to *both*. Next, we fitted a multivariable regression model
156 that included an IYCF-by-PCoA axis 1 score interaction term and prespecified covariates. The regression
157 model was restricted to 53 infants who had a fecal specimen collected at the 6mo follow-up visit when
158 IYCF started and used their covariate values at the 6mo visit (Figure S2), and stunting status at 18mo was
159 used as the dependent variable. We repeated our analyses using PCoA axis 2 to 4 scores. Finally, we
160 fitted regression models replacing stunting status with LAZ at 18mo as the dependent variable.

161 Greater PCoA axis 1 scores represented species turnover with increasing infant age (Figure S3), while
162 greater PCoA axis 2 scores represented changes in species composition associated with mother-infant
163 FUT2+/FUT3- phenotypes (Figure S3). PCoA axis 1 and 2 scores showed evidence of interaction with IYCF
164 on stunting at 18mo (Table 2), but not LAZ (Table S4). Amongst infants randomized to IYCF, those with

165 higher PCoA axis 1 scores at age 6mo were less likely to be stunted at 18mo compared to infants with
166 lower PCoA axis 1 scores (difference-in-differences -76.0%[95%CI: -99.0%,-32.0%, adjusted p=0.003)
167 (Table 2). In contrast, infants randomized to IYCF with higher PCoA axis 2 scores at age 6mo were more
168 likely to be stunted at 18mo compared to infants who had lower PCoA axis 2 scores (difference-in-
169 differences, 14.0%[95%CI: 7.0%,21.0%], adjusted p=0.001) (Table 2). Taken together, our findings
170 showed that infant age-related microbiome species turnover was associated with greater reduction in
171 the probability of stunting at 18mo by IYCF, indicating greater efficacy of the intervention; while
172 microbiome species composition related to mother-infant FUT2+/FUT3- phenotype was associated with
173 lesser reduction in stunting, suggesting variation in microbiome composition due to these infant
174 characteristics is an important determinant of SQ-LNS efficacy to reduce stunting.

175

176 *Infant age and mother-infant FUT2+/FUT3- phenotype explain microbiome species turnover, in*
177 *particular, Bifidobacterium longum*

178 To investigate sources of variation in infant intestinal microbiome composition and derive
179 interpretable measures of species turnover, we performed constrained PCoA of Bray-Curtis
180 dissimilarities with permutational analysis of variance using distance matrices for hypothesis testing.
181 Infant age at stool collection explained 12.6% (ADONIS2 p=0.001) of the variability in microbiome
182 composition (Table S5). Notably, exclusive breastfeeding (EBF) at 3mo was not significantly associated
183 ($R^2=0.346$, ADONIS2 p=0.483) with microbiome composition (Table S5). However, 93.2% of mothers in
184 these analyses reported exclusive breastfeeding (Table S6). Thus, there may not have been sufficient
185 variability in infant breastfeeding practices in this cohort to identify EBF-associated differences between
186 infant microbiomes. Also, inclusion of specimens collected throughout the follow-up period in our PCoA
187 models may have obscured associations with EBF, since EBF is only recommended up to age 6mo.

188 We then fitted a fully adjusted multivariable constrained PCoA model that included both infant age
189 at stool collection and mother-infant FUT2+/FUT3- phenotype. We retained the latter variable to
190 capture variation in microbiota composition associated with mother-infant FUT2/FUT3 status after
191 controlling for infant age, because of our *a priori* aim to investigate whether microbiome variation due
192 to mother and infant FUT2/FUT3 phenotype was a modifier of the IYCF intervention, and our finding
193 that the *mother only* FUT2+/FUT3- group was associated with a modified intervention effect. In the full
194 model, age explained 12.8% (ADONIS p=0.001) and mother-infant FUT2+/FUT3- phenotype explained
195 0.81% (ADONIS p=0.323) of the variance in microbiome composition (Table S5), indicating that infant
196 age was the main driver of microbiome-wide species-turnover in this cohort.

197 Age-related species turnover was characterized by decreased relative abundance of *B. longum*, and
198 increased relative abundance of *Prevotella copri*, *Faecalibacterium prausnitzii*, *Dorea longicatena*, and
199 *Dorea formicigenerans* (Figure S4). Mother-infant FUT2+/FUT3- discordance was characterized by
200 increased relative abundance of *B. longum* in the *none* and *infant only* groups (Figure S5-S7).

201 In combination with our IYCF-by-PCoA effect modification models (see previous section), these
202 findings indicate that infant age-associated species turnover characterized by a shift away from a
203 microbiome dominated by *B. longum* (i.e. greater PCoA axis 1 score) was associated with a reduction in
204 the probability of stunting at age 18mo in infants randomized to IYCF (Table 2). In contrast, species
205 composition associated with mother-infant FUT2+/FUT3- phenotype (i.e. greater PCoA axis 2 score),
206 which was characterized by higher *B. longum* abundance, showed evidence of reduced impact of IYCF on
207 stunting (Table 2).

208
209 *Bifidobacterium longum* relative abundance modifies the effect of the IYCF intervention on stunting at
210 18mo

211 To determine if differences in the relative abundances of specific microbiome species that
212 characterized the constrained PCoA axes were also associated with significant modification of IYCF on
213 stunting or LAZ at 18mo, we fitted multivariable regression models that included IYCF-by-species relative
214 abundance interaction terms and prespecified covariates as described in the previous sections. These
215 models were restricted to 53 infants who had a fecal specimen collected at the 6mo follow-up visit
216 when IYCF started and used their covariate values at that visit (Figure S2). We fitted a separate model
217 for each microbiome species of interest. Infants randomized to IYCF who had greater relative abundance
218 of *B. longum* when the intervention started were more likely to be stunted at age 18mo compared to
219 infants with lower relative abundance of *B. longum* (differences-in-differences 50.0%[95%CI:
220 26.0%,74.0%], adjusted $p < 0.001$) (Table 3). No other species-level interactions with IYCF on stunting
221 were identified (Table 3). Infants randomized to IYCF with greater *B. longum* relative abundance also
222 had smaller LAZ at 18mo compared to infants with lower *B. longum* abundance; however, this
223 association was not statistically significant after FDR-adjustment (differences-in-differences -0.88[95%CI:
224 -1.45,-0.31], adjusted $p = 0.074$) (Table S7). Overall, our findings indicate that greater relative abundance
225 of *B. longum* in the infant gut microbiome at initiation of the IYCF intervention was associated with less
226 efficacy of the IYCF intervention to reduce stunting at age 18mo.

227
228 *Infants randomized to IYCF in the mother only FUT2+/FUT3- group or with lower B. longum relative*
229 *abundance were spared from more severe growth faltering*

230 To investigate whether these reductions in IYCF efficacy were due to differences in the degree or
231 timing of growth faltering, we plotted (i) LAZ growth trajectories and (ii) LAZ velocities (sd/mo) from 6-
232 18mo of age, by both IYCF arm and paired mother-infant FUT2+/FUT3- phenotype. Infants randomized
233 to IYCF in the *mother only* group had a less steep decline in LAZ trajectories on average compared to
234 infants in the *mother only* group randomized to no IYCF (Figure 1). In addition, although all groups of

235 infants had negative 6-18mo LAZ velocities on average, infants in the *mother only* group who were
236 randomized to IYCF had higher LAZ velocity on average (-0.02 sd/mo, 95%CI[-0.05,0.00]) compared to
237 those in the no IYCF group (-0.08 sd/mo, 95%CI[-0.11,-0.05]) (Figure 1). Importantly, infants in the
238 *mother only* group also benefitted more from the IYCF intervention in our interaction models (Table 1).

239 We repeated these exploratory analyses to compare LAZ trajectories and LAZ velocities by both IYCF
240 arm and *B. longum* at the 6mo visit stratified above or below the relative abundance median. Infants
241 randomized to IYCF who were above the median relative abundance of *B. longum* had declining growth
242 trajectories on average, while infants below the median did not (Figure 2). Furthermore, the mean 6-
243 18mo LAZ velocity was negative in both *B. longum* groups, but trended toward being higher in the group
244 with relative abundance below (-0.02 sd/mo, 95%CI[-0.07,0.03]) compared to above (-0.08 sd/mo
245 95%CI[-0.12,-0.03]) the median; however, the 95% confidence intervals overlapped. In contrast, among
246 infants randomized to no IYCF, both those with a relative abundance above and those with a relative
247 abundance below the median at the 6mo visit had declining growth trajectories (Figure 2) with similar
248 average negative LAZ velocities (Figure 2).

249 Overall, these results indicate that the differences in IYCF efficacy by mother-infant FUT2+/FUT3-
250 phenotype and *B. longum* relative abundance can be explained by differences in LAZ velocity. Infants in
251 the *mother only* FUT2+/FUT3- group and infants with lower *B. longum* relative abundance at 6mo were
252 spared from more severe LAZ declines, which contributed to a lower probability of stunting at 18mo,
253 even when the differences in velocity were not statistically significant.

254
255 *Bifidobacterium longum* strains most similar to subspecies *infantis* dominate the early infant gut
256 microbiome

257 Next, we aimed to identify whether infants carried different strains of *B. longum* using a pangenome
258 approach. We used PanPhlan3.0⁵² to generate UniProt gene family profiles of dominant *B. longum*

259 strains from 218 infant gut metagenomes, generated from 136 infant, with sufficient coverage of *B*
260 *.longum* (Figure S2). To assess similarities between SHINE *B. longum* strains and previously characterized
261 subspecies, we also included UniProt gene family profiles produced by PanPhlan for 118 reference
262 strains. We performed PCoA using Jaccard dissimilarities calculated from these gene family presence or
263 absence profiles. Three clusters of *B. longum* strains were identifiable by visualization of ordination plots
264 (Figure 3 and S8). We, therefore, performed hierarchical clustering of these Jaccard dissimilarities to
265 delineate three distinct strain clusters and place each strain into the most appropriate cluster (Figure
266 S8). Subspecies *infantis* reference strains predominantly grouped with the largest cluster of strains
267 (hereafter called the *infantis* cluster) and included 15 *infantis* reference strains and 255 SHINE strains
268 (Figure 3). Subspecies *longum* reference strains predominantly grouped with the second largest cluster
269 of strains (*longum* cluster), including 29 *longum*, 3 *infantis*, 64 *unclassified* subspecies strains and 14
270 SHINE strains. The remaining cluster included two subspecies *suis*, one subspecies *longum*, 4 *unclassified*
271 subspecies reference strains and 15 SHINE strains (*suis* cluster) (Figure 3 and Figure S8).

272
273 *The infant gut microbiome undergoes a transition with age in which Bifidobacterium longum strains*
274 *most similar to subspecies infantis become less prevalent*

275 To investigate predictors of *B. longum* relative abundance in infants over time, we fitted a
276 longitudinal multivariable zero-inflated mixed-effects model, using 225 specimens from 87 infants with
277 prespecified, non-missing covariate data. Covariates included infant age at specimen collection, sex, EBF
278 at 3mo, minimum infant dietary diversity at specimen collection, and mother-infant FUT2+/FUT3-
279 phenotypes (Figure S2). Infant age and mother-infant FUT2+/FUT3- phenotype were significant
280 predictors of *B. longum* relative abundance. Each one month increase in infant age was associated with
281 a 0.91-fold decrease (95%CI:0.90,0.92, $p < 0.001$) in *B. longum*, and the *mother only* FUT2+/FUT3- group

282 had the lowest relative abundance of *B. longum* throughout follow-up (Figure S11) with a 0.71-fold
283 decrease in relative abundance (95%CI:0.59,0.87, p=0.001) relative to the *both* group (Table S9).

284 Also, to determine predictors of *B. longum* strain cluster detection in infants over time, we fitted
285 multivariable longitudinal logistic regression models using 133 specimens from 70 infants with
286 PanPhlan3.0 output and prespecified, non-missing covariate data (Figure S2). We fitted a separate
287 model for each strain to estimate its probability of detection. Results were consistent with predictors of
288 *B. longum* relative abundance. Each one month increase in infant age was associated with a 0.85-fold
289 decreased odds (95%CI:0.75,0.96, p=0.008) of the *infantis* cluster (Table S10). At the same time, the *suis*
290 and *longum* clusters increased with age (Table S10 & Figure S12). Female infants had 8.35-fold increased
291 odds (95%CI:3.17,21.97, p<0.001), and the *infant only* FUT2+/FUT3- group, which had the highest
292 probability of the *infantis* cluster throughout follow-up (Figure S13A), had a 4.66-fold increased odds
293 (95%CI:1.05,20.71, p=0.043) of the *infantis* cluster (Table S10). In contrast, the *mother only* FUT2+/FUT3-
294 group had low probability of carrying an *infantis* cluster strain (Figure S13A & Table S10) and the highest
295 probability of carrying a *suis* cluster strain (Figure S13C).

296 In summary, *B. longum* decreased with infant age and was lowest among infants in the *mother only*
297 FUT2+/FUT3- group. The *infantis* cluster, which included the dominant *B. longum* strains, also decreased
298 with infant age. Furthermore, *infantis* cluster strains were most likely to be detected in the *infant only*
299 group, and less likely to be detected in the *mother only* group which were more likely to carry *suis*
300 cluster strains. Infant age and mother-infant FUT2+/FUT3- phenotype were important determinants of
301 both *B. longum* relative abundance and strain carriage.

302

303 *Bifidobacterium longum* strains most similar to subspecies *infantis* were characterized by greater
304 capacity for HMO degradation, uptake, siderophore and antimicrobial biosynthesis

305 To identify differences in metabolic potential between *B. longum* strain clusters, we used two-sided
306 Fisher's Exact tests to compare UniProt gene family presence between clusters. We restricted these
307 analyses to the 284 SHINE *Bifidobacterium* pangenomes in order to make inferences about differences
308 in metabolic potential between SHINE strains. We then performed overrepresentation analyses⁵³ of
309 differentially frequent gene families by one-sided Fisher's Exact test to determine whether they were
310 more likely to be involved in specific GO biological processes⁵⁴, or to function as specific carbohydrate-
311 active enzymes (CAZymes)⁵⁵ or transporters⁵⁶. Gene families that were more common in the *infantis*
312 cluster were more likely to be involved in HMO degradation, and included genes that function as
313 CAZyme Glycoside Hydrolase Family 20 (GH20) (β -N-acetylglucosaminidases, β -N-
314 acetylgalactosaminidase, β -6-SO₃-N-acetylglucosaminidases, and lacto-N-biosidases), GH29
315 (fucosidases), GH95 (fucosidases), and GH33 (sialidases) (Figure 4A, Table S8). Conversely, gene families
316 that were more common in the other clusters were more likely to be involved in degradation of plant-
317 derived polysaccharides, including genes that function as GH42 (β -galactosidases), GH51 (L-
318 arabinofuranosidases) and GH127 (β -L-arabinofuranosidase) CAZymes (Figure 4A, Table S8). Similarly,
319 gene families that were more common in the *infantis* cluster were more likely to function as
320 transporters involved in oligosaccharide uptake (TCID 3.A.1.1.59), while those that were less common in
321 the *infantis* cluster were more likely to be involved in uptake of fructose and other sugars (TCID
322 3.A.1.2.23) (Figure 4A, Table S8). Other differences between strain clusters included greater carriage of
323 gene families among *infantis* cluster strains that are involved in riboflavin biosynthesis, signal
324 transduction, amino acid catabolism and uptake.

325 We also identified differences between strain clusters in the frequency of 115 MetaCyc⁵⁷ pathways
326 identified using MinPath⁵⁸ (Figure S10). Pathways that were more common in the *infantis* cluster were
327 more likely to be involved in generation of precursor metabolites and energy, and secondary metabolite
328 biosynthesis (which predominantly included pathways for biosynthesis of siderophores and

329 antimicrobials) (Figure 4B, Table S8). Conversely, the *infantis* clusters was less likely to include pathways
330 involved in glycan metabolism and polymeric compound degradation (e.g. pectin, xylan, and
331 arabinogalactan degradation pathways), and in fatty acid and lipid biosynthesis (Figure 4B, Table S8).

332 Overall, infant gut microbiomes were dominated by *B. longum* strains that were most similar to
333 subspecies *infantis* in their UniProt gene family profiles. The primary distinction of *B. longum* strains in
334 the *infantis* cluster was greater capacity for HMO degradation and uptake of oligosaccharides than
335 plant-derived polysaccharides. However, strains in the *infantis* cluster also had greater capacity for
336 siderophore and antimicrobial production, and displayed differences in their capacity for riboflavin, fatty
337 acid, and lipid metabolism.

338

339 Discussion

340 In this study of HIV-unexposed infants enrolled in the SHINE trial in rural Zimbabwe, we tested the
341 hypothesis that mother-infant FUT2/FUT3 phenotype and infant gut microbiome modify the effect of an
342 intervention containing small-quantity lipid based nutrient supplements, on infant stunting and LAZ at
343 18mo of age. Our goal was to define mechanisms that explain the rather modest effects of SQ-LNS on
344 linear growth, reasoning that maternal-infant HBGA phenotypes might be important given their
345 combined role in shaping the early-life microbiome. We found that the following features were
346 associated with reduced IYCF impact on stunting at 18mo: (i) discordance in mother-infant FUT2+/FUT3-
347 phenotype, where the mother has the phenotype but the infant does not; (ii) changes in microbiome
348 species composition that reflected a shift from a *B. longum*-dominant microbiome to a microbiome with
349 less *B. longum* and a greater abundance of species characteristic of older infants; and (iii) differences in
350 *B. longum* abundance that were also associated with FUT+/FUT3- status. These findings suggest that a
351 persistently “younger” microbiome, characterized by a high abundance of *B. longum* and carriage of *B.*
352 *longum* strains best suited to HMO metabolism, at the point when complementary foods are introduced

353 into the infant diet, may reduce the beneficial effects of an intervention that includes SQ-LNS on infant
354 stunting.

355 The *mother only* FUT2+/FUT3- group showed evidence of a greater reduction in stunting following
356 receipt of one year of the IYCF intervention. Mother-infant FUT2+/FUT3- phenotype was also a
357 significant predictor of *B. longum*, whereby relative abundance was lower throughout follow-up in the
358 *mother only* group. Active maternal FUT2/FUT3 genes are key determinants of milk oligosaccharide
359 composition³¹⁻³³. Human milk specimens form distinct groups based on maternal FUT2⁵⁹ and FUT3
360 phenotype^{31,33} by principal component analyses of oligosaccharide composition. In particular,
361 FUT2+/FUT3- mothers are a subset of FUT2+ women who form an HMO cluster that is distinct from
362 mothers with other phenotypes, including FUT2+ mothers who are also FUT3+^{31,33}. Differences in HMO
363 composition influence growth and activity of Bifidobacterium populations in the infant gut^{28,59}. FUT2
364 status may also affect infant gut microbiome composition³⁶⁻⁴⁰. Gut Bifidobacterium³⁹, Bacteroides^{36,38},
365 Faecalibacterium⁴⁰ and Roseburia⁴⁰ are differentially abundant in FUT2+ compared to FUT2- individuals.
366 However, reported differences in microbiome composition by FUT2/FUT3 status have been inconsistent,
367 potentially due to variability in age, dietary patterns, host health, sampled gut sections and
368 methodology between studies^{60,614}, and studies predominantly include from adults. However, CAZymes
369 found in *B. longum* species that function in HMO degradation (GH29 and GH95) have also been found to
370 function in host intestinal glycan degradation in infants⁶². The evidence, therefore, suggests that the
371 FUT2/FUT3 phenotypes of mother and infant, together, can elicit a strong prebiotic selective pressure,
372 driven by maternal milk and infant glycan composition²⁸ that influences Bifidobacteria and broader gut
373 microbiota composition in infants.

374 In contrast to our finding that mother-infant FUT2+/FUT3- phenotype predicted the presence of *B.*
375 *longum* subspecies *infantis* cluster strains, a prior study reported that maternal or infant FUT2 or FUT3
376 status did not predict the abundance subspecies *infantis* or *longum* in children⁶³. However, we included

377 infant age as a covariate in our models, while the prior study did not⁶³. In addition, to accommodate the
378 fact that FUT2 and FUT3 work in concert biologically to produce different HBGAs and HMOs, we defined
379 combined FUT2 and FUT3 phenotypes (Figure S1). Furthermore, we considered paired maternal and
380 infant phenotypes⁶³. Another smaller study found infants born to FUT2+/FUT3- mothers had lower
381 bifidobacterial operational taxonomic unit diversity compared to other infants³⁹. This study provides
382 additional evidence that maternal FUT2+/FUT3- phenotype is associated with bifidobacterial taxon
383 composition in the infant gut. Further research is needed to clarify the roles of mother-infant
384 FUT2/FUT3, maternal HMO and the infant glyco biome in driving infant gut microbiome composition and
385 development.

386 In our PCoA model, infant age-related species turnover predominantly reflected decreased
387 abundance of *B. longum* and increased abundance of *P. copri*, *F. prausnitzii*, *D. longicatena*, and *D.*
388 *formicigenerans*. These species were also important predictors of infant age in a microbiome-age model
389 previously developed from this same cohort⁶⁴. Age-discriminatory taxa in the same genera were also
390 identified in previously reported microbiome-age models¹⁴. Delayed gut microbiota-age has been
391 reported in children with severe acute malnutrition (SAM), while improvements in microbiota-age and
392 relative abundance of age-discriminatory taxa have been correlated with better growth¹⁴. Our analyses
393 complement this literature with evidence that infant age-related species turnover in the gut microbiome
394 increased the effect of the IYCF intervention on stunting at 18mo, while greater relative abundance of *B.*
395 *longum*, an age-discriminatory taxon which is associated with younger age, reduced the effect. This
396 suggests that delayed maturation of the gut microbiome at the point when complementary foods are
397 introduced and IYCF is initiated, may impair IYCF-induced effects on growth.

398 Infant age was the strongest determinant of *B. longum* relative abundance over time. This is
399 consistent with previous reports⁶⁵. In breastfed infants, Bifidobacteria are the most abundant gut
400 bacteria^{65,66}. Human breast milk is rich in oligosaccharides, which Bifidobacteria preferentially utilize⁶⁷.

401 At introduction of solid foods, a wider variety of nutrients and reduced availability of HMOs correspond
402 to an increase in microbiota diversity, a decrease in Bifidobacterium,⁶⁸ greater bacterial diversity,
403 evenness and development of a more adult-like composition by 2–3 years of age^{11,69–71}.

404 Utilization of HMOs by Bifidobacterium varies between species and strains^{72–78}. We identified three
405 clusters of dominant *B. longum* strains that also varied by infant age and mother-infant FUT2+/FUT3-
406 phenotype. The cluster of strains with pangenomes most similar to subspecies *infantis* had the highest
407 prevalence in early infancy. However, by age 18mo there was a marked decrease in detection of *infantis*
408 cluster strains and a corresponding increase in detection of strains with pangenomes most similar to
409 subspecies *suis*, which had the highest prevalence at 18mo. Strains most similar to subspecies *longum*
410 increased more slowly. This finding is consistent with a recent study that also reported a pattern of
411 succession among three distinct gut *B. longum* clades from birth to 24mo of age. Subspecies *infantis* was
412 dominant in early infancy but peaked at age 6mo and decreased considerably thereafter. While a
413 transitional clade that included strains most similar to subspecies *suis* and *suillum* showed a
414 corresponding increase in abundance that peaked by 18mo, and subspecies *longum* expanded from
415 15mo-24mo of age⁷⁹. In that report, the transitional *suis/suillum* clade harbored functional capacity to
416 degrade both HMOs and dietary polysaccharides, suggesting it may be an adaptation of the infant gut
417 microbiome to a period when breastfeeding may co-occur with introduction of complementary foods⁷⁹.
418 We add to this work by showing that differences between mother and infant in FUT2+/FUT3- phenotype
419 may also play a role in driving this transition, whereby, throughout follow-up, the *mother only*
420 FUT2+/FUT3- group had a low prevalence of the *infantis* cluster and the highest prevalence of the *suis*
421 cluster; while the *infantis* cluster was most prevalent in the *infant only* group.

422 *B. longum* subspecies *infantis* are particularly well adapted for HMO utilization^{80,81}. *B. longum*
423 subspecies *longum*, on the other hand, do not grow as well on HMO, and are more specialized for
424 utilization of diet-derived polysaccharides⁸². In our analyses, UniProt gene families that were more

425 frequent in the *infantis* cluster were more likely to be involved in HMO degradation and uptake. Two of
426 CAZyme families more likely to be carried by the *infantis* cluster (GH29⁸³ and GH33⁷⁴) were previously
427 reported as more prevalent in subspecies *infantis* strains. In contrast, UniProt gene families that were
428 less frequent in the *infantis* cluster were more likely to be involved in uptake of fructose and other
429 simple sugars, including the sugar transporter 3.A.1.2.23, which was previously described in a different
430 *B. longum* subspecies⁸⁴. Furthermore, strains in the *suvis* and *longum* clusters were more likely to carry
431 UniProt gene families involved in such MetaCyc pathways as pectin, xylan, and arabinogalactan
432 degradation. UniProt gene families found more frequently in *infantis* cluster strains were also more
433 likely to be involved in siderophore and antimicrobial biosynthesis. Heavy metals such as iron and zinc
434 are essential minerals for nearly all bacteria and their mammalian hosts. Strategies utilized by bacteria
435 to acquire heavy metals include siderophore biosynthesis. Siderophores are low molecular weight iron-
436 chelating compounds that are synthesized by bacteria to scavenge iron and other essential metals such
437 as zinc under nutrient-restricted conditions⁸⁵. For example, Bifidobacterium species isolated from iron-
438 deficient children efficiently sequester iron via siderophore production⁸⁶. Siderophores may provide a
439 competitive advantage to Bifidobacteria⁸⁷, which along with antimicrobial biosynthesis⁸⁸, may also help
440 protect the infant gut from enteric pathogens that require essential metals for colonization. However,
441 essential metals such as iron and zinc are key components in SQ-LNS formulations⁸⁹⁻⁹¹, and produce
442 improvements in linear growth and reductions in stunting risk^{92,936}. While siderophore activity varies
443 considerably between Bifidobacterium species and strains, no research to date has investigated
444 sequestration of essential metals by subspecies *infantis* strains commonly found in resource-limited
445 settings. Our analyses suggest that greater abundance of *B. longum*, at the time when IYCF is started,
446 characterized by a predominance of strains with carriage of gene families which confer greater capacity
447 for HMO utilization and siderophore biosynthesis, is associated with reduced impact on stunting at
448 18mo. These suggests potential mechanisms by which a “younger” microbiome can constrain the

449 beneficial effects of an SQ-LNS intervention on infant stunting. However, more research is required to
450 fully elucidate the biological mechanisms and downstream pathways to stunting that may be involved.

451 Our results are in contrast to a previous RCT that investigated infant microbiome composition as a
452 modifier of SQ-LNS impact on infant growth in Malawi⁴⁸. However, in the primary analyses of that RCT,
453 there was no effect of SQ-LNS on linear infant growth⁹⁴. Furthermore, SQ-LNS was provided to both
454 mothers during pregnancy and infants starting at 6mo postpartum, active control interventions (iron-
455 folate or multiple micronutrient supplements) were provided to mothers^{48,94}, and 16S rRNA gene
456 amplification and sequencing were used which can affect taxon detection (including *Bifidobacterium*)
457 results⁹⁵. A second RCT reported evidence for effect modification of iron supplementation on growth by
458 maternal FUT2 status, where infants of FUT2- mothers randomized to iron supplementation showed
459 greater declines in LAZ than infants of FUT2+ mothers⁹⁶. In addition, a third, recent RCT found that
460 suppression of *B. longum* by amoxicillin allowed the gut microbiota of children with SAM to better adapt
461 to a solid-food diet by reducing the abundance of taxa specialized for breast milk utilization, resulting in
462 improved anthropometric indicators of infant nutritional status⁹⁷. However, it is essential to note that *B.*
463 *longum* subspecies *infantis* is a critical early infant gut bacteria with important benefits for infant health,
464 including protection from enteric pathogens⁹⁸, immune system development⁹⁹, and reducing asthma
465 risk¹⁰⁰. *B. longum* subspecies *infantis* also improved ponderal growth when administered to infants
466 ~4mo of age with SAM in two RCTs^{101,102}. However, the effects on LAZ were not statistically significant.
467 Our work complements this literature. Our findings suggest that a shift to away from a “less mature”
468 microbiome, characterized by a high abundance of *B. longum* and carriage of strains that are better
469 suited to HMO metabolism, may be critical to support efficacy of nutrient supplements that start with
470 the introduction of complementary feeding; and we identify maternal drivers of early infant *B. longum*
471 abundance and strain carriage which, if further elucidated, may be employed to shape the infant
472 microbiome into a more favorable composition at this critical time in infancy.

473 There are some limitations of this work. First, from our cohort of 1169 HIV-unexposed, uninfected
474 infants, we had microbiome data on 172 infants. However, infants included in our analyses were
475 comparable to excluded infants (Table S6). Also, mother-infant FUT2+/FUT3- phenotype, which was an
476 important determinant of *B. longum* abundance and strain cluster detection, did modify the impact of
477 IYCF on infant growth in the larger sample of 792 infants without measured microbiome data in a way
478 that was consistent with our microbiome results. That said, our small sample size may have limited
479 power to detect effect modification by other taxa that are indicative of a “more mature” post-weaning
480 microbiome. Finally, our analyses were not able to investigate effect modification by actual microbial
481 metabolic activity, maternal HMO composition or infant gut glycobiome, which would require multi-
482 omics approaches such as metatranscriptomics and metabolomics.

483 In conclusion, we present analyses of moderators of IYCF impact on infant stunting at 18mo in an
484 RCT of IYCF using SQ-LNS in rural Zimbabwe. We report that (i) the impact of IYCF on stunting risk at
485 18mo is reduced by infant age-related changes in microbiome species composition characterized by a
486 shift from *B. longum* dominance, particularly *B. longum* strains that are most similar to the proficient
487 HMO utilizer subspecies *infantis*; (ii) discordance in mother-infant FUT2+/FUT3- phenotype was
488 associated with reduced IYCF impact on stunting risk; and (iii) *B. longum* relative abundance was also
489 determined by mother-infant FUT2+/FUT3- phenotype. Future work should investigate how differences
490 between maternal HMOs and infant HBGAs determine gut Bifidobacterium species and strain
491 composition, and investigate how to tailor interventions at the introduction of complementary feeding
492 to balance infant nutritional needs with age-related microbiome composition and function to prevent
493 stunting.

494

495

496

497 **Figure legends**

498 **Figure 1. Infant growth trajectories and growth velocities vary by IYCF arm and mother-infant**
499 **FUT2+/FUT3- phenotype.**

500 (A) LAZ by infant age from 1-18mo (n=792), stratified by IYCF arm (light grey, no IYCF; dark grey, IYCF)
501 and mother-infant FUT2+/FUT3- phenotype (*both, none, infant only or mother only*). Lines illustrate
502 average trajectories. Shaded areas are 95% confidence bands. Infants randomized to IYCF in the *mother*
503 *only* group had a less steep decline in LAZ trajectories on average compared to infants randomized to no
504 IYCF.

505 (B) Violin plots of LAZ velocity from 6-18mo of age, stratified by IYCF arm (light grey, no IYCF; dark grey,
506 IYCF) and mother-infant FUT2+/FUT3- phenotype (*both, none, infant only or mother only*). Open circles
507 with error bars in the center of each panel indicate mean LAZ velocity and 95% CIs. All groups of infants
508 had negative LAZ velocities on average, but infants in the *mother only* group who were randomized to
509 IYCF had higher LAZ velocity on average, contributing to a less steep decline in LAZ over time and a
510 smaller proportion of infants stunted at 18mo.

511

512 **Figure 2. Infant growth trajectories and growth velocities vary by IYCF arm and infant gut**
513 ***Bifidobacterium longum* relative abundance.**

514 (A) LAZ by infant age from 1-18mo (n=53), stratified by IYCF arm and *Bifidobacterium longum* relative
515 abundance (light grey, \leq median relative abundance; dark grey, $>$ median relative abundance). Thin lines
516 illustrate individual trajectories. Thick lines show average trajectories. Infants randomized to IYCF who
517 were above the median relative abundance had a declining growth trajectory on average, while infants
518 below the median did not.

519 (B) Violin plots of LAZ velocity from 6-18mo of age, stratified by IYCF arm (light grey, no IYCF; dark grey,
520 IYCF) and mother-infant FUT2+/FUT3- phenotype (*both, none, infant only or mother only*). Open circles

521 with error bars indicate mean LAZ velocity and 95% CIs. All groups of infants had negative LAZ velocities
522 on average. However, LAZ velocity trended toward being higher in the group with relative abundance
523 below the median. The 95% confidence intervals overlap, but the higher LAZ velocity contributed to a
524 less steep decline in LAZ over time and a smaller proportion of stunted infants at 18mo.

525

526 **Figure 3. *Bifidobacterium longum* strains most similar to subspecies *infantis* dominate the early infant**

527 **gut microbiome.** Ordination plots of PCoA with Jaccard dissimilarities calculated using the pangenome

528 profiles of dominant *Bifidobacterium longum* strains in fecal specimens (N=284) generated using

529 PanPhlan3.0. Three clusters of *B. longum* strains were identifiable. Individual strains and indicated by

530 small circles. Those in the same cluster are enclosed by a large ellipse and are differentiated by both the

531 color of the ellipse and the border color of the small circle (blue, *infantis*; dark green, *longum*; red, *suis*).

532 Filled small circles indicate reference strains (light blue, *infantis*; pink, *suis*, light green, *longum*; grey,

533 *unclassified*). Open small circles indicate SHINE strains. Subspecies *infantis* reference strains

534 predominantly grouped with the largest cluster (blue ellipse, *infantis* cluster). Subspecies *longum*

535 reference strains predominantly grouped with the second largest cluster (dark green ellipse, *longum*

536 cluster). The remaining cluster (red ellipse, *suis* cluster) grouped with subspecies *suis* and *longum*.

537

538 **Figure 4. SHINE infant *Bifidobacterium longum infantis* cluster strains are better adapted for human**

539 **milk oligosaccharide utilization and protection against pathogens than *suis* and *longum* cluster strains.**

540 (A) Heatmap of UniProt gene family presence in SHINE infant *Bifidobacterium longum* strains (N=284).

541 UniProt gene family presence is indicated in grey. The horizontal bar at the top indicates strain cluster

542 (blue, *infantis*; dark green, *longum*; red, *suis*). Vertical bars from left to right indicate: UniProt gene

543 families that differed in prevalence between the *infantis* and *longum* cluster by two-sided Fisher's Exact

544 test after FDR correction (red); UniProt gene families that differed in prevalence between the *infantis*

545 and *suis* cluster by two-sided Fisher's Exact test after FDR correction (red); Biological Process GO groups;
546 CAZymes; and Transporter class. Only gene families with evidence of overrepresentation in a Biological
547 Process, CAZyme or Transporter class by one-sided Fisher's Exact Test are presented.

548 (B) Heatmap of MetaCyc pathway presence in SHINE infant *Bifidobacterium longum* strains (N=284).
549 MetaCyc pathway presence is indicated in grey. The horizontal bar at the top indicates strain cluster
550 (blue, *infantis*; dark green, *longum*; red, *suis*). Vertical bars from left to right indicate: MetaCyc pathways
551 that differed in prevalence between the *infantis* and *longum* cluster by two-sided Fisher's Exact test
552 after FDR correction (red); MetaCyc pathways that differed in prevalence between the *infantis* and *suis*
553 cluster by two-sided Fisher's Exact test after FDR correction (red); MetaCyc pathway type. Only
554 pathways with evidence of overrepresentation in a pathway type by one-sided Fisher's Exact Test are
555 presented.

556
557 **Figure S1. Flow chart of pathways for histo-blood group antigen synthesis by functional FUT2 and**
558 **FUT3 status.** The type 2 precursor includes β 1-4 rather than β 1-3 bonds and α 1-3 rather than α 1-4
559 bonds. The light-gray shaded region of the chart indicates non-secretor (FUT2-), Lewis-positive (FUT3+)
560 pathways that produce the FUT2-/FUT3+ phenotype (Lewis Le^a). Pathways outside the light-gray shaded
561 region of the chart produce secretor (FUT2+) phenotypes. In this outside region, the area enclosed by
562 gray dashed lines indicates pathways that produce the FUT2+/FUT3+ (Lewis Le^b), while the area outside
563 the gray dashed lines indicates the pathways that produce the FUT2+/FUT3- phenotype (Le^{a-b}).

564
565 **Figure S2. Flow of participants through the SHINE trial and the analyses reported in this study.** The
566 Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial enrolled 5280 pregnant women, of whom 3937
567 were HIV-negative. Of these HIV-negative pregnant women, 1153 and their 1169 live-born infants were
568 recruited into a sub-study to investigate biomarkers of environmental enteric dysfunction. FUT2 and

569 FUT3 phenotypes were ascertained in 792 of these infants and their mothers. 172 of these infants
570 provided at least 1 fecal specimen for shotgun metagenomic sequencing (354 fecal specimens). 218 of
571 these fecal metagenomes, from 136 infants, plus an additional 66 fecal metagenomes from 43
572 infants in whom mother and infant FUT2 and FUT3 phenotypes were not ascertained, had sufficient
573 coverage of the *Bifidobacterium longum* genome for pangenome analysis by PanPhlan3.0. 53 infants had
574 metagenomic data at the 6mo follow-up visit and were included in regression analyses to determine
575 effect modification of IYCF by the infant microbiome.

576

577 **Figure S3. Infant age and mother-infant FUT2+/FUT3- phenotype significantly explain variation in**
578 **infant gut microbiome composition.** Ordination biplots for a multivariable constrained PCoA model that
579 included both infant age and mother-infant FUT2+/FUT3- phenotype (N=354 metagenomes from 172
580 infants). The x-axis represents PCoA axis 1 scores in all panels.

581 (A) The y-axis represents PCoA axis 2, and points are colored from light pink to red to indicate younger
582 to older infant age (mo) at which fecal specimens were taken.

583 (B-C) The y-axes represent PCoA axes 2-4, and points are colored to indicate mother-infant FUT2+/FUT3-
584 phenotype concordance, (black, *both* mother and infant are FUT2+/FUT3-; red, *none* are FUT2+/FUT3-;
585 green, *infant only* is a FUT2+/FUT3-; blue, *mother only* is a FUT2+/FUT3-). Arrows parallel to PCoA axes
586 are correlated with PCoA scores and arrow length is proportional to the variance explained by a variable.

587

588 **Figure S4. Infant age-related microbiome species turnover predominantly reflects decreased relative**
589 **abundance of *Bifidobacterium longum* and increased abundance of *Prevotella copri*, *Faecalibacterium***
590 ***prausnitzii*, *Dorea longicatena*, and *Dorea formicigenerans*.** Barplot of microbiome species (x-axis)
591 versus the 20 highest and 20 lowest PCoA axis 1 loadings (y-axis) from a multivariable constrained PCoA
592 model that included both infant age and mother-infant FUT2+/FUT3- phenotype (N=354 metagenomes

593 from 172 infants). Green bars indicate species positively loaded on PCoA axis 1 that are more abundant
594 with increasing infant age, and red bars indicate species negatively loaded on PCoA axis 1 that are less
595 abundant with increasing infant age.

596

597 **Figure S5. Mother-infant FUT2+/FUT3- phenotype-related microbiome species turnover**

598 **predominantly reflects increased relative abundance of *Bifidobacterium longum*.** Barplot of

599 microbiome species (x-axis) versus the 20 highest and 20 lowest PCoA axis 2 loadings (y-axis) from a

600 multivariable constrained PCoA model that included both infant age and mother-infant FUT2+/FUT3-

601 phenotype concordance (N=354 metagenomes from 172 infants). Green bars indicate species positively

602 loaded on PCoA axis 2 that, relative to the *both* group, are more abundant in infants in the *none*

603 FUT2+/FUT3- group and red bars indicate species negatively loaded on PCoA axis 2 that, relative to the

604 *both* group, are more abundant in infants in the *infant only* FUT2+/FUT3- group.

605

606 **Figure S6. Mother-infant FUT2+/FUT3- phenotype-related microbiome species turnover.** Barplot of

607 microbiome species (x-axis) versus the 20 highest and 20 lowest PCoA axis 3 loadings (y-axis) from

608 multivariable constrained PCoA model that included both infant age and mother-infant FUT2+/FUT3-

609 phenotype concordance (N=354 metagenomes from 172 infants). Green bars indicate species positively

610 loaded on PCoA axis 3 that, relative to the *both* group, are more abundant in infants the *mother only*

611 FUT2+/FUT3- group, and red bars indicate species negatively loaded on PCoA axis 3 that, relative to the

612 *both* group, are more abundant in infants in the *none* FUT2+/FUT3- group.

613

614 **Figure S7. Mother-infant FUT2+/FUT3- phenotype-related microbiome species turnover.** Barplot of

615 microbiome species (x-axis) versus the 20 highest and 20 lowest PCoA axis 4 loadings (y-axis) from a

616 multivariable constrained PCoA model that included both infant age and mother-infant FUT2+/FUT3-

617 phenotype concordance (N=354 metagenomes from 172 infants). Green bars indicate species positively
618 loaded on PCoA axis 4 that, relative to the *both* group, are more abundant in infants in the *infant only*
619 FUT2+/FUT3- group, and red bars indicate species negatively loaded on PCoA axis 4 that, relative to the
620 *both* group, are more abundant in infants in the *mother only* FUT2+/FUT3- group.

621
622 **Figure S8. *Bifidobacterium longum* strains most similar to subspecies *infantis* dominate the early**
623 **infant gut microbiome.** Heatmap of UniProt gene family presence in *B. longum* strains (N=284 SHINE
624 strains and 118 reference strains). UniProt gene family presence is indicated in grey. The horizontal bars
625 at the top from topmost to bottommost row indicate: strain source (black, reference strain; white,
626 SHINE strain); reference strain subspecies (light blue, *infantis*; light green, *longum*; pink, *suis*; grey,
627 *unclassified*), and strain cluster (blue, *infantis*; dark green, *longum*; red, *suis*). Clusters were defined by
628 hierarchical clustering of Jaccard dissimilarities, and cluster membership was determined by cutting the
629 cluster dendrogram at a height that would produce three clusters (horizontal gray line). Rows are
630 ordered using the default hierarchical clustering settings of *heatmap3*.

631
632 **Figure S9. SHINE infant *Bifidobacterium longum* strains in the *infantis* cluster differ from other infant**
633 ***B. longum* strain clusters in their UniProt gene family profiles.** Heatmap of UniProt gene family
634 presence in SHINE infant *B. longum* strains (N=284). UniProt gene family presence is indicated in grey.
635 The horizontal bar at the top indicates strain cluster (blue, *infantis*; dark green, *longum*; red, *suis*).
636 Vertical bars from left to right indicate: UniProt gene families that differed in prevalence between the
637 *infantis* and *longum* cluster by two-sided Fisher's Exact test after FDR correction (red); UniProt gene
638 families that differed in prevalence between the *infantis* and *suis* cluster by two-sided Fisher's Exact test
639 after FDR correction (red).

640

641 **Figure S10. SHINE infant *Bifidobacterium longum* strains in the *infantis* cluster differ from other infant**
642 ***B. longum* strain clusters in their MetaCyc pathway profiles.** Heatmap of MetaCyc pathway presence in
643 SHINE infant *B. longum* strains (N=284) as determined by MinPath. MetaCyc pathway presence is
644 indicated in grey. The horizontal bar at the top indicates strain cluster (blue, *infantis*; dark green,
645 *longum*; red, *suis*). Vertical bars from left to right indicate: MetaCyc pathways that differed in prevalence
646 between the *infantis* and *longum* cluster by two-sided Fisher's Exact test after FDR correction (red);
647 MetaCyc pathways that differed in prevalence between the *infantis* and *suis* cluster by two-sided
648 Fisher's Exact test after FDR correction (red).

649
650 **Figure S11. The infant gut microbiome undergoes a transition over time characterized by a decrease in**
651 ***Bifidobacterium longum* relative abundance.** Multivariable zero-inflated mixed-effects model fitted to
652 longitudinal data (N=225 specimens from 87 infants). Infant age and mother-infant FUT2+/FUT3-
653 phenotype were significant predictors of *B. longum* relative abundance. The model was used to predict
654 the mean *B. longum* relative abundance (y-axis) which was plotted against infant age (mo) at follow-up
655 (x-axis), conditional on model covariates. Mother-infant FUT2+/FUT3- phenotypes are differentiated by
656 color (black, *both*; red, *none*; green, *infant only*; blue, *mother only* are FUT2+/FUT3-).

657
658 **Figure S12. The infant gut microbiome undergoes a transition over time in which *Bifidobacterium***
659 ***longum* strains most similar to subspecies *infantis* become less prevalent and strains most similar to**
660 **subspecies *suis* or *longum* become more prevalent.** Multivariable logistic regression models were fitted
661 to longitudinal data (N=133 specimens from 70 infants) with detection of each strain cluster as the
662 dependent variable. A separate model was fitted for each strain cluster. Each model was used to predict
663 the probability of detecting a *B. longum* strain in the specified cluster (y-axis) which was plotted against
664 infant age (mo) at follow-up (x-axis), conditional on model covariates. Line colors indicate strain cluster

665 (blue, *infantis*; green, *longum*; red, *suis*). *Infantis* cluster strains were most likely to be detected
666 throughout follow-up, but decreased in detection probability over time and was lowest at 18mo of age.
667 While the probability of detecting *longum* and *suis* cluster strains increased with infant age. *Suis* cluster
668 strain detection probabilities increased with age more than *longum* cluster strain detection and peaked
669 at 18mo of age, where it was more likely to be detected than strains in the *infantis* cluster.

670

671 **Figure S13. The dominance of *Bifidobacterium longum* strains most similar to subspecies *infantis***
672 **varies by mother-infant FUT2+/FUT3- phenotype.** Multivariable logistic regression models were fitted
673 to longitudinal data (N=133 specimens from 70 infants) with detection of each strain cluster as the
674 dependent variable. A separate model was fitted for each strain cluster. Each model was used to predict
675 the probability of detecting a *B. longum* strain in the specified cluster (y-axis) which was plotted against
676 infant age (mo) at follow-up (x-axis) and mother-infant FUT2+/FUT3- phenotype, conditional on model
677 covariates. Mother-infant FUT2+/FUT3- phenotypes are differentiated by color (black, *both*; red, *none*;
678 green, *infant only*; blue, *mother only* are FUT2+/FUT3-). The *infant only* group had the highest
679 probability of the *infantis* cluster throughout follow-up. While the *mother only* group had a lower
680 probability of carrying an *infantis* cluster strain. The *mother only* group also had the highest probability
681 of carrying a *suis* cluster strain.

682 (A) *infantis* cluster strain detection.

683 (B) *longum* cluster strain detection.

684 (C) *suis* cluster strain detection.

685

686

687

688

689

690 **STAR Methods**

691 *Study design and participants*

692 The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial was a 2x2 factorial cluster-randomized
693 trial that enrolled 5280 pregnant women at a median age of 12.5 weeks gestation between November
694 2012 and March 2015 to test the impact of improved household water quality, sanitation, and hygiene
695 (WASH) and improved infant and young child feeding (IYCF) via provision of SQ-LNS to the infant from
696 age 6mo-18mo, on linear growth and anemia at age 18mo. A detailed description of the SHINE trial
697 design and methods has been published^{51,103}.

698 Briefly, research nurses made home visits twice during pregnancy and at infant ages 1, 3, 6, 12, and
699 18 months. At baseline, maternal education and age, household wealth¹⁰⁴, existing water and sanitation
700 services, and household food security¹⁰⁵ were assessed, and mothers were tested for HIV via a rapid
701 testing algorithm. Infant birth date, weight, and delivery details were transcribed from health facility
702 records. Gestational age at delivery was calculated from the date of the mother's last menstrual period
703 ascertained at baseline. Infant weight, length, and mid-upper arm circumference were measured at
704 every postnatal visit. Nurses were standardized against a gold-standard anthropometrist every 6
705 months, with retraining provided to those who failed to meet predefined criteria.

706 Part-way through the trial (from mid-2014 onwards) mother-infant pairs were invited to join a
707 substudy to collect additional biological specimens. Women were informed about the substudy at their
708 32-week gestation visit and those with live births were enrolled at the 1-month postnatal visit, or as
709 soon as possible thereafter^{106,107}.

710

711

712

713 *Specimen collection and processing*

714 Mothers collected fecal specimens prior to the research nurse visit. Fecal specimens were placed in
715 a cold box and transported to the field laboratory, where they were stored at -80°C until transfer to the
716 central laboratory in Harare for long-term archiving at -80°C, with generator back-up. Fecal specimens
717 were transferred via private courier on dry ice from Harare, Zimbabwe to Vancouver, British Columbia
718 for metagenomic analyses.

719 The Qiagen DNeasy PowerSoil Kit was used to extract total DNA from 200mg of feces, according to
720 manufacturer's instructions. Paired-end libraries were constructed using the Illumina TruSeq kit and
721 using New England Biosystem TruSeq compatible library preparation reagents. Libraries were sequenced
722 at the British Columbia Genome Sciences Centre using the Illumina HiSeq 2500 platform. Forty-eight
723 libraries were pooled and included per sequencing lane. Negative controls were included to capture
724 microbial contamination in the DNA extraction and library preparation steps.

725 The analyses presented here utilize data and specimens from HIV-uninfected mothers and their
726 infants enrolled in the specimen collection substudy. The fecal microbiome was characterized in 354
727 specimens collected from 172 HIV-unexposed infants from 1 to 18mo of age. A mean(sd) of 2.0(1.0)
728 samples were analyzed per child. Infants included in these analyses largely resembled the population of
729 live-born infants from the wider SHINE trial who were not included in these analyses (Table S6).
730 However, infants in the current analyses had slightly older mothers and longer gestational ages, and
731 fewer were born during the hungry season, but more were in a household that met the minimum
732 dietary diversity score (Table S6). Overall, the majority were born by vaginal delivery (91.6%) in an
733 institution (91.5%) and were exclusively breastfed (83.2% at 3 months). The prevalence of stunting was
734 26.9% at 18mo in this sub-study (Table S6).

735

736

737 *Bioinformatics*

738 Sequenced reads were trimmed of adapters and filtered to remove low-quality, short (<60 base-
739 pairs), and duplicate reads, as well as those of human, other animal or plant origin using KneadData with
740 default settings. Overall, 354 unique whole metagenome sequencing datasets were used from fecal
741 specimens collected from 1mo to 18mo from 172 infants with available mother and infant FUT2 and
742 FUT3 phenotypes (Figure S2). On average, 10.8 ± 3.7 million paired end quality-filtered reads were
743 generated per sample. Assessment of negative controls and technical variation have been previously
744 reported⁶⁴. Species composition was determined by mapping reads to clade-specific markers using
745 MetaPhlan3, while functional gene and metabolic pathway composition was determined using
746 HUMAnN3 against the UniRef90 database, both with default settings⁵². Bacterial species and pathway
747 abundance estimates were normalized to relative abundances. UniProt gene family profiles were
748 generated for dominant *B. longum* strains in fecal metagenomes with sufficient coverage for
749 pangenome analysis using PanPhlan3⁵². To facilitate interpretation of UniProt gene family profiles, the
750 minimum set of biological pathways sufficient to explain the gene families identified in each strain was
751 determined using MinPath with default settings⁵⁸ and the MetaCyc database⁵⁷.

752

753 *Assessment of FUT2 and FUT3 status*

754 Saliva samples were collected by oral swab from mothers and infants. Available saliva from any
755 follow-up visit was selected to assess FUT2 and FUT3 status. Secretor versus non-secretor (FUT2) and
756 Lewis-positive versus Lewis-null (FUT3) status were ascertained for infants and their mothers using a
757 previously reported phenotyping assay¹⁰⁸. We defined FUT2 and FUT3 phenotype combinations as
758 Lewis-positive non-secretors (FUT2-/FUT3+), Lewis-positive secretors (FUT+/FUT3+), or Lewis-null
759 secretors (FUT2+/FUT3-) (Table S11) according to the histo-blood group antigen synthesis pathways

760 defined in Figure S1. Paired mother-infant phenotype concordance or discordance was defined as
761 presented in Table S1.

762 Of 1,169 mother-infant pairs, 999 (85.4%) mothers and 1104 (94.4%) infants were tested. Of these,
763 FUT2 or FUT3 status could be determined in 889 (76.0%) and 999 (85.4%) mothers and infants,
764 respectively (Table S11). Of those whose FUT2 or FUT3 status could be ascertained, secretors were the
765 most frequent FUT2 phenotype (88.1% and 85.6% in mothers and infants respectively), while Lewis-
766 positive was the most frequent FUT3 phenotype (76.8% and 74.9% in mothers and infants, respectively)
767 (Table S11). Most mothers and infants were Lewis-positive secretors (60.5% and 64.9%, respectively),
768 followed by FUT2+/FUT3- (25.1% and 23.2%, respectively), and Lewis-positive non-secretors (14.4% and
769 11.9%, respectively) (Table S1).

770

771 *Statistical analyses*

772 Infant characteristics that explain species β -diversity were evaluated using constrained principal
773 coordinates analysis (PCoA) of Bray-Curtis dissimilarities (*capscale*)¹⁰⁹. Characteristics of interest
774 included factors that are known to be correlated with microbiome composition (infant age, sex, EBF at
775 3mo, dietary diversity, maternal and infant FUT2 and FUT3 phenotype). Statistical significance was
776 tested by permutational analysis of variance using distance matrices with 1000 permutations
777 (*adonis2*)¹¹⁰. We then developed a final multivariable constrained PCoA model that included covariates
778 which explained a significant fraction ($p < 0.05$) of the variance in microbiome composition (infant age at
779 specimen collection), as well as mother-infant FUT2+/FUT3- discordance given our *a priori* hypothesis
780 that FUT2 and FUT3 phenotypes are important determinants of infant microbiome composition and our
781 finding that mother-infant FUT2+/FUT3- discordance was an important modifier of IYCF efficacy to
782 reduce stunting at 18mo. Constrained PCoA axis scores in the final multivariable model represented

783 changes in microbiome composition (species turnover) along gradients defined by each infant
784 characteristic included in the full model.

785 Since the IYCF intervention was started at the 6mo follow-up visit, we assessed interaction between
786 randomization to IYCF and mother-infant FUT2+/FUT3- discordance or microbiome composition using
787 data from the 6mo visit as covariates. The primary outcome was stunting at 18mo and LAZ at 18mo was
788 a secondary outcome. We fitted separate models for stunting and LAZ at 18mo. Interaction was
789 assessed on the additive risk difference scale, which is most appropriate for statistical estimation of
790 synergistic biological effects¹¹¹. We used generalized linear models (*glm*) with a Gaussian distribution, an
791 identity link, sandwich standard errors (*sandwich*)¹¹² and an IYCF-by-mother-infant FUT2+/FUT3-
792 phenotype interaction term. We repeated these analyses using IYCF-by-PCoA axis score interaction
793 terms, where PCoA axis scores were derived from the final multivariable constrained PCoA model. One
794 model was fitted per constrained PCoA axis. For species that were strongly associated with PCoA axis
795 scores (loadings > 0.5 or < -0.5), analyses were repeated to assess IYCF-by-species interactions. We fitted
796 a separate model for each species of interest. Models also included IYCF, infant sex, mother-infant
797 FUT2+/FUT3- discordance, infant age at specimen collection, an indicator of whether infants met the
798 minimum dietary diversity score at specimen collection, and LAZ at specimen collection. We did not
799 include WASH arm because, in prior analyses, the SHINE WASH intervention did not affect stunting or
800 LAZ at 18mo⁵¹ nor infant gut microbiome composition⁶⁴. P-values were adjusted for multiple hypothesis
801 testing to preserve the false discovery rate¹¹³.

802

803 *Identification and analysis of Bifidobacterium longum strain clusters*

804 *B. longum* strain profiles produced with PanPhlan3.0, which indicate whether UniProt gene families
805 are present in a strain¹¹⁴, were converted to Jaccard dissimilarity matrices and visualized by PCoA to
806 ascertain the existence of strain clusters (*capscale*). Three clusters were identified, and strain cluster

807 membership was determined by hierarchical clustering of Jaccard dissimilarities and Ward's error sum of
808 squares algorithm (*hclust*)¹¹⁵. Hierarchical clustering dendrograms were cut at a height to obtain three
809 clusters.

810 Differences in UniProt gene family profiles between *B. longum* strain clusters were determined by
811 two-sided Fisher's Exact test (*fisher.test*), with adjustment for multiple hypothesis testing to preserve
812 the false discovery rate¹¹³, and were visualized using heatmaps (*heatmap3*). 3260 UniProt gene families
813 were differentially present between strain clusters after FDR-adjustment. We performed
814 overrepresentation analyses⁵³ using one-sided Fisher's Exact tests (*fisher.test*) to determine whether the
815 differentially present gene families were more likely to function as particular CAZymes⁵⁵ or
816 transporters⁵⁶, or in specific GO biological processes⁵⁴. These analyses were repeated using the
817 biological pathways determined with MinPath⁵⁸. 115 pathways were differentially present between
818 strain clusters after FDR-adjustment. We performed overrepresentation analyses of these pathways to
819 determine whether they were more likely to have particular biological functions defined by MetaCyc
820 pathway types.

821

822 *Predictors of Bifidobacterium relative abundance and strain detection*

823 Predictors of *B. longum* relative abundance over time were assessed using mixed-effects zero-
824 inflated beta regression estimated by restricted maximum likelihood (*glmlss*)¹¹⁶. The model included
825 infant age at specimen collection, sex, EBF at 3mo, minimum infant dietary diversity at specimen
826 collection, and mother-infant FUT2+/FUT3- discordance, with random intercepts (*re*) and a first order
827 autocorrelation structure (*corCAR1*).

828 Predictors of *B. longum* strain cluster were assessed by logistic regression (*glm*) using an indicator of
829 strain cluster presence as the dependent variable, with the same covariates, and sandwich standard
830 errors. An individual model was fitted separately for each cluster. Bias corrected¹¹⁷ logistic regression

831 was used to facilitate stable parameter estimation due to separation resulting from the small sample
832 size¹¹⁸.

833 All statistical analyses were conducted in R version 4.2.0. PCoA and adonis2 were performed using
834 the *vegan* package¹¹⁹. Heatmaps were generated with *heatmap3*. Mixed-effects zero-inflated beta
835 regression was performed using the *gamlss* package¹²⁰. Bias corrected logistic regression models were
836 fitted using the *brglm2* package. Sandwich standard errors were generated with the *sandwich* package.

837

838 **Ethics approvals**

839 All SHINE mothers provided written informed consent. The Medical Research Council of Zimbabwe
840 (MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University
841 of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome
842 analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940).

843

844 **Acknowledgments**

845 We thank all the mothers, babies, and their families who participated in the SHINE trial and all members
846 of the SHINE trial team (all members listed here: <https://doi.org/10.1093/cid/civ844>). We particularly
847 thank the leadership and staff of the Ministry of Health and Child Care in Chirumanzu and Shurugwi
848 districts and Midlands Province (especially environmental health, nursing, and nutrition) for their roles
849 in operationalization of the study procedures, the Ministry of Local Government officials in each district
850 who supported and facilitated field operations, Phillipa Rambanepasi and her team for proficient
851 management of all the finances, Virginia Sauramba for management of compliance issues, and the
852 programme officers at the Bill & Melinda Gates Foundation and the Department for International
853 Development (UK Aid), who enthusiastically worked with us over a long period to make SHINE happen.

854 Funding was from the Bill & Melinda Gates Foundation (OPP1021542 and OPP1143707; J.H.H. and
855 A.J.P.), with a subcontract to the University of British Columbia (20R25498; A.R.M.). United Kingdom
856 Department for International Development (DFID/UKAID; J.H.H. and A.J.P.). Wellcome Trust
857 (093768/Z/10/Z, 108065/Z/15/Z, 206455/Z/17/Z, 203905/Z/16/Z and 210807/Z/18/Z; A.J.P., R.C.R. and
858 C.E.). Swiss Agency for Development and Cooperation (J.H.H. and A.J.P.). US National Institutes of Health
859 (2R01HD060338-06; J.H.H.). UNICEF (PCA-2017-0002; J.H.H. and A.J.P.). The Nutricia Research
860 Foundation (2021-52; E.K.G.) The funders had no role in the design of the study and collection, analysis,
861 and interpretation of data and in writing the manuscript.

862

863 **Author contributions:** A.R.M., L.E.S., R.J.S., M.N.N.M., J.H.H. and A.J.P. conceptualized and designed the
864 study. K.M., R.N., B.C., F.D.M., N.V.T., J.T., and B.M. collected data and biospecimens. H.M.G., I.B.,
865 S.K.G., R.C.R., F.F. and L.C. processed fecal specimens. M.K. conducted laboratory analyses to ascertain
866 FUT2 and FUT3 status. C.E., J.C. and E.K.G. developed the FUT2 and FUT3 analysis plan. E.K.G. developed
867 and conducted the microbiome statistical analysis plan. T.J.E. and E.K.G. conducted bioinformatics.
868 A.R.M. and E.K.G. analyzed and interpreted the data. E.K.G. wrote the original manuscript draft. All
869 authors reviewed the manuscript. A.R.M., A.J.P. and J.H.H. supervised and verified the data.

870

871 **Declaration of interests:** T.J.E. was paid a scientific consulting fee in relation to the analysis of the data
872 presented here by the Zvitambo Institute for Maternal and Child Health Research. All other authors
873 declare no competing interests.

874

875

876

877 **References**

- 878 1. United Nations Children’s Fund, World Health Organization, and The World Bank (2019). Levels
879 and trends in child malnutrition: key findings of the 2019 Edition of the Joint Child Malnutrition
880 Estimates – UNICEF Regions. (United Nations Children’s Fund (UNICEF), World Health Organization,
881 International Bank for Reconstruction and Development/The World Bank).
- 882 2. Onis, M.D., Garza, C., Onyango, A.W., and Martorell, R. (2006). WHO child growth standards. *Acta*
883 *Paediatrica* 95, 1–104.
- 884 3. Benjamin-Chung, J., Mertens, A., Colford, J.M., Hubbard, A.E., van der Laan, M.J., Coyle, J.,
885 Sofrygin, O., Cai, W., Nguyen, A., Pokpongkiat, N.N., et al. (2023). Early-childhood linear growth
886 faltering in low- and middle-income countries. *Nature* 621, 550–557.
- 887 4. Gough, E.K., Moodie, E.E.M., Prendergast, A.J., Ntozini, R., Moulton, L.H., Humphrey, J.H., Manges,
888 A.R., Stephens, D.A., Moodie, E.E.M., Prendergast, A.J., et al. (2016). Linear growth trajectories in
889 Zimbabwean infants. *American Journal of Clinical Nutrition* 104, 1616–1627.
- 890 5. Adair, L.S.L.L.S., Fall, C.H.D.D., Osmond, C., Stein, A.D.A.A.D., Martorell, R., Ramirez-Zea, M.,
891 Sachdev, H.S., Dahly, D.L., Bas, I., Norris, S.A., et al. (2013). Associations of linear growth and
892 relative weight gain during early life with adult health and human capital in countries of low and
893 middle income: Findings from five birth cohort studies. *The Lancet* 382, 525–534.
- 894 6. Victora, C.G., Adair, L., Fall, C., Hallal, P.C., Martorell, R., Richter, L., and Sachdev, H.S. (2008).
895 Maternal and child undernutrition: consequences for adult health and human capital. *Lancet* 371,
896 340–357.
- 897 7. Vollmer, S., Harttgen, K., Subramanyam, M.A., Finlay, J., Klasen, S., and Subramanian, S.V. (2014).
898 Association between economic growth and early childhood undernutrition: evidence from 121
899 Demographic and Health Surveys from 36 low-income and middle-income countries. *The Lancet*
900 *Global Health* 2, e225-234.
- 901 8. Dewey, K.G., Wessells, K.R., Arnold, C.D., Prado, E.L., Abbeddou, S., Adu-Afarwuah, S., Ali, H.,
902 Arnold, B.F., Ashorn, P., Ashorn, U., et al. (2021). Characteristics that modify the effect of small-
903 quantity lipid-based nutrient supplementation on child growth: an individual participant data
904 meta-analysis of randomized controlled trials. *Am J Clin Nutr* 114, 15S-42S.
- 905 9. Dewey, K.G., Arnold, C.D., Wessells, K.R., Prado, E.L., Abbeddou, S., Adu-Afarwuah, S., Ali, H.,
906 Arnold, B.F., Ashorn, P., Ashorn, U., et al. (2022). Preventive small-quantity lipid-based nutrient
907 supplements reduce severe wasting and severe stunting among young children: an individual
908 participant data meta-analysis of randomized controlled trials. *Am J Clin Nutr* 116, 1314–1333.
- 909 10. Ruel, M.T., Alderman, H., and Maternal Child Nutrition Study Group (2013). Nutrition-sensitive
910 interventions and programmes: how can they help to accelerate progress in improving maternal
911 and child nutrition? *Lancet* 382, 536–551.
- 912 11. Arrieta, M.-C., Stiemsma, L.T., Amenogbe, N., Brown, E.M., and Finlay, B. (2014). The intestinal
913 microbiome in early life: health and disease. *Frontiers in Immunology* 5, 427.

- 914 12. Jones, H.J., Bourke, C.D., Swann, J.R., and Robertson, R.C. (2023). Malnourished Microbes: Host-
915 Microbiome Interactions in Child Undernutrition. *Annual Review of Nutrition* 43, 327–353.
- 916 13. Robertson, R.C., Manges, A.R., Finlay, B.B., and Prendergast, A.J. (2019). The Human Microbiome
917 and Child Growth - First 1000 Days and Beyond. *Trends Microbiol* 27, 131–147.
- 918 14. Subramanian, S., Huq, S., Yatsunenkov, T., Haque, R., Mahfuz, M., Alam, M.A., Benezra, A.,
919 DeStefano, J., Meier, M.F., Muegge, B.D., et al. (2014). Persistent gut microbiota immaturity in
920 malnourished Bangladeshi children. *Nature* 510, 417–421.
- 921 15. Zhao, G., Vatanen, T., Droit, L., Park, A., Kostic, A.D., Poon, T.W., Vlamakis, H., Siljander, H.,
922 Härkönen, T., Hämäläinen, A.M., et al. (2017). Intestinal virome changes precede autoimmunity in
923 type I diabetes-susceptible children. *Proceedings of the National Academy of Sciences of the*
924 *United States of America* 114, E6166–E6175. 10.1073/pnas.1706359114.
- 925 16. Ho, N.T., Li, F., Lee-Sarwar, K.A., Tun, H.M., Brown, B.P., Pannaraj, P.S., Bender, J.M., Azad, M.B.,
926 Thompson, A.L., Weiss, S.T., et al. (2018). Meta-analysis of effects of exclusive breastfeeding on
927 infant gut microbiota across populations. *Nature Communications* 9, 4169. 10.1038/s41467-018-
928 06473-x.
- 929 17. Reyes, A., Blanton, L.V., Cao, S., Zhao, G., Manary, M., Trehan, I., Smith, M.I., Wang, D., Virgin,
930 H.W., Rohwer, F., et al. (2015). Gut DNA viromes of Malawian twins discordant for severe acute
931 malnutrition. *Proceedings of the National Academy of Sciences of the United States of America*
932 112, 11941–11946. 10.1073/pnas.1514285112.
- 933 18. Gough, E.K., Stephens, D.A., Moodie, E.M., Prendergast, A.J., Stoltzfus, R.J., Humphrey, J.H., and
934 Manges, A.R. (2016). Linear growth faltering in infants is associated with *Acidaminococcus* sp. and
935 community-level changes in the gut microbiota. *Microbiome* 3, 24.
- 936 19. Ghosh, T.S., Gupta, S.S., Bhattacharya, T., Yadav, D., Barik, A., Chowdhury, A., Das, B., Mande, S.S.,
937 and Nair, G.B. (2014). Gut Microbiomes of Indian Children of Varying Nutritional Status. *PLoS ONE*
938 9, e95547.
- 939 20. Gupta, S.S., Mohammed, M.H., Ghosh, T.S., Kanungo, S., Nair, G.B., and Mande, S.S. (2011).
940 Metagenome of the gut of a malnourished child. *Gut Pathog* 3, 7.
- 941 21. Huey, S.L., Jiang, L., Fedarko, M.W., McDonald, D., Martino, C., Ali, F., Russell, D.G., Udipi, S.A.,
942 Thorat, A., Thakker, V., et al. (2020). Nutrition and the Gut Microbiota in 10- to 18-Month-Old
943 Children Living in Urban Slums of Mumbai, India. *mSphere* 5, e00731-20.
- 944 22. Digitale, J., Sié, A., Coulibaly, B., Ouermi, L., Dah, C., Tapsoba, C., Bärnighausen, T., Lebas, E., Arzika,
945 A.M., Glymour, M.M., et al. (2020). Gut Bacterial Diversity and Growth among Preschool Children
946 in Burkina Faso. *Am J Trop Med Hyg* 103, 2568–2573.
- 947 23. Collard, J.-M., Andrianonimiadana, L., Habib, A., Rakotondrainipiana, M., Andriantsalama, P.,
948 Randriamparany, R., Rabenandrasana, M. a. N., Weill, F.-X., Sauvonnnet, N., Rendremanana, R.V., et
949 al. (2022). High prevalence of small intestine bacteria overgrowth and asymptomatic carriage of
950 enteric pathogens in stunted children in Antananarivo, Madagascar. *PLoS Negl Trop Dis* 16,
951 e0009849.

- 952 24. Kamng'ona, A.W., Young, R., Arnold, C.D., Kortekangas, E., Patson, N., Jorgensen, J.M., Prado, E.L.,
953 Chaima, D., Malamba, C., Ashorn, U., et al. (2019). The association of gut microbiota characteristics
954 in Malawian infants with growth and inflammation. *Scientific Reports* 9.
- 955 25. Perin, J., Burrowes, V., Almeida, M., Ahmed, S., Haque, R., Parvin, T., Biswas, S., Azmi, I.J., Bhuyian,
956 S.I., Talukder, K.A., et al. (2020). A Retrospective Case-Control Study of the Relationship between
957 the Gut Microbiota, Enteropathy, and Child Growth. *The American journal of tropical medicine and*
958 *hygiene*.
- 959 26. Brown, E.M., Wlodarska, M., Willing, B. p, Vonaesch, P., Han, J., Reynolds, L.A., Arriet, M.-C., Uhrig,
960 M., Scholz, R., Partida, O., et al. (2015). Diet and specific microbial exposure trigger features of
961 environmental enteropathy in a novel murine model. *Nature Communications* 6, 7806.
- 962 27. Kau, A.L., Planer, J.D., Liu, J., Rao, S., Yatsunencko, T., Trehan, I., Manary, M.J., Liu, T.-C.,
963 Stappenbeck, T.S., Maleta, K.M., et al. (2015). Functional characterization of IgA-targeted bacterial
964 taxa from undernourished Malawian children that produce diet-dependent enteropathy. *Science*
965 *Translational Medicine* 7, 276ra24-276ra24.
- 966 28. Salli, K., Hirvonen, J., Siitonen, J., Ahonen, I., Anglenius, H., and Maukonen, J. (2021). Selective
967 Utilization of the Human Milk Oligosaccharides 2'-Fucosyllactose, 3-Fucosyllactose, and
968 Difucosyllactose by Various Probiotic and Pathogenic Bacteria. *Journal of Agricultural and Food*
969 *Chemistry* 69.
- 970 29. Davis, J.C.C., Totten, S.M., Huang, J.O., Nagshbandi, S., Kirmiz, N., Garrido, D.A., Lewis, Z.T., Wu,
971 L.D., Smilowitz, J.T., German, J.B., et al. (2016). Identification of Oligosaccharides in Feces of
972 Breast-fed Infants and Their Correlation with the Gut Microbial Community*. *Molecular & Cellular*
973 *Proteomics* 15, 2987–3002.
- 974 30. Charbonneau, M.R., O'Donnell, D., Blanton, L.V., Totten, S.M., Davis, J.C.C., Barratt, M.J., Cheng, J.,
975 Guruge, J., Talcott, M., Bain, J.R., et al. (2016). Sialylated Milk Oligosaccharides Promote
976 Microbiota-Dependent Growth in Models of Infant Undernutrition. *Cell* 164, 859–871.
- 977 31. Mank, M., Hauner, H., Heck, A.J.R., and Stahl, B. (2020). Targeted LC-ESI-MS2 characterization of
978 human milk oligosaccharide diversity at 6 to 16 weeks post-partum reveals clear staging effects
979 and distinctive milk groups. *Anal Bioanal Chem* 412, 6887–6907.
- 980 32. Castanys-Muñoz, E., Martin, M.J., and Prieto, P.A. (2013). 2'-fucosyllactose: an abundant,
981 genetically determined soluble glycan present in human milk. *Nutr Rev* 71, 773–789.
- 982 33. Blank, D., Dotz, V., Geyer, R., and Kunz, C. (2012). Human milk oligosaccharides and Lewis blood
983 group: individual high-throughput sample profiling to enhance conclusions from functional studies.
984 *Adv Nutr* 3, 440S-9S.
- 985 34. Schneider, M., Al-Shareffi, E., and Haltiwanger, R.S. (2017). Biological functions of fucose in
986 mammals. *Glycobiology* 27, 601–618.
- 987 35. Cooling, L. (2015). Blood groups in infection and host susceptibility. *Clinical Microbiology Reviews*
988 28.

- 989 36. Tong, M., McHardy, I., Ruegger, P., Goudarzi, M., Kashyap, P.C., Haritunians, T., Li, X., Graeber,
990 T.G., Schwager, E., Huttenhower, C., et al. (2014). Reprogramming of gut microbiome energy
991 metabolism by the FUT2 Crohn's disease risk polymorphism. *ISME J* 8, 2193–2206.
- 992 37. Rausch, P., Rehman, A., Künzel, S., Häslér, R., Ott, S.J., Schreiber, S., Rosenstiel, P., Franke, A., and
993 Baines, J.F. (2011). Colonic mucosa-associated microbiota is influenced by an interaction of crohn
994 disease and FUT2 (Secretor) genotype. *Proceedings of the National Academy of Sciences of the*
995 *United States of America* 108.
- 996 38. Gampa, A., Engen, P.A., Shobar, R., and Mutlu, E.A. (2017). Relationships between gastrointestinal
997 microbiota and blood group antigens. *Physiol Genomics* 49, 473–483.
- 998 39. Wacklin, P., Mäkituokko, H., Alakulppi, N., Nikkilä, J., Tenkanen, H., Rabinä, J., Partanen, J., Aranko,
999 K., and Mättö, J. (2011). Secretor genotype (FUT2 gene) is strongly associated with the
1000 composition of bifidobacteria in the human intestine. *PLoS ONE* 6, e20113.
- 1001 40. Rühlemann, M.C., Hermes, B.M., Bang, C., Doms, S., Moitinho-Silva, L., Thingholm, L.B., Frost, F.,
1002 Degenhardt, F., Wittig, M., Kässens, J., et al. (2021). Genome-wide association study in 8,956
1003 German individuals identifies influence of ABO histo-blood groups on gut microbiome. *Nat Genet*
1004 53, 147–155.
- 1005 41. Christensen, L., Vuholm, S., Roager, H.M., Nielsen, D.S., Krych, L., Kristensen, M., Astrup, A., and
1006 Hjorth, M.F. (2019). Prevotella Abundance Predicts Weight Loss Success in Healthy, Overweight
1007 Adults Consuming a Whole-Grain Diet Ad Libitum: A Post Hoc Analysis of a 6-Wk Randomized
1008 Controlled Trial. *J Nutr* 149, 2174–2181.
- 1009 42. Eriksen, A.K., Brunius, C., Mazidi, M., Hellström, P.M., Risérus, U., Iversen, K.N., Fristedt, R., Sun, L.,
1010 Huang, Y., Nørskov, N.P., et al. (2020). Effects of whole-grain wheat, rye, and lignan
1011 supplementation on cardiometabolic risk factors in men with metabolic syndrome: a randomized
1012 crossover trial. *Am J Clin Nutr* 111, 864–876. 10.1093/ajcn/nqaa026.
- 1013 43. Shin, J.-H., Jung, S., Kim, S.-A., Kang, M.-S., Kim, M.-S., Joung, H., Hwang, G.-S., and Shin, D.-M.
1014 (2019). Differential Effects of Typical Korean Versus American-Style Diets on Gut Microbial
1015 Composition and Metabolic Profile in Healthy Overweight Koreans: A Randomized Crossover Trial.
1016 *Nutrients* 11, E2450.
- 1017 44. Hjorth, M.F., Roager, H.M., Larsen, T.M., Poulsen, S.K., Licht, T.R., Bahl, M.I., Zohar, Y., and Astrup,
1018 A. (2018). Pre-treatment microbial Prevotella-to-Bacteroides ratio, determines body fat loss
1019 success during a 6-month randomized controlled diet intervention. *Int J Obes (Lond)* 42, 580–583.
- 1020 45. Li, Y., Wang, D.D., Satija, A., Ivey, K.L., Li, J., Wilkinson, J.E., Li, R., Baden, M., Chan, A.T.,
1021 Huttenhower, C., et al. (2021). Plant-Based Diet Index and Metabolic Risk in Men: Exploring the
1022 Role of the Gut Microbiome. *J Nutr* 151, 2780–2789.
- 1023 46. Li, J., Li, Y., Ivey, K.L., Wang, D.D., Wilkinson, J.E., Franke, A., Lee, K.H., Chan, A., Huttenhower, C.,
1024 Hu, F.B., et al. (2022). Interplay between diet and gut microbiome, and circulating concentrations
1025 of trimethylamine N-oxide: findings from a longitudinal cohort of US men. *Gut* 71, 724–733.

- 1026 47. Wang, D.D., Nguyen, L.H., Li, Y., Yan, Y., Ma, W., Rinott, E., Ivey, K.L., Shai, I., Willett, W.C., Hu, F.B.,
1027 et al. (2021). The gut microbiome modulates the protective association between a Mediterranean
1028 diet and cardiometabolic disease risk. *Nat Med* 27, 333–343.
- 1029 48. Hughes, R.L., Arnold, C.D., Young, R.R., Ashorn, P., Maleta, K., Fan, Y.-M., Ashorn, U., Chaima, D.,
1030 Malamba-Banda, C., Kable, M.E., et al. (2020). Infant gut microbiota characteristics generally do
1031 not modify effects of lipid-based nutrient supplementation on growth or inflammation: secondary
1032 analysis of a randomized controlled trial in Malawi. *Sci Rep* 10, 14861.
- 1033 49. Smith, M.I., Yatsunenkov, T., Manary, M.J., Trehan, I., Mkakosya, R., Cheng, J., Kau, A.L., Rich, S.S.,
1034 Concannon, P., Mychaleckyj, J.C., et al. (2013). Gut microbiomes of Malawian twin pairs discordant
1035 for Kwashiorkor. *Science* 339, 548–554.
- 1036 50. Schwarzer, M., Makki, K., Storelli, G., Machuca-Gayet, I., Srutkova, D., Hermanova, P., Martino,
1037 M.E., Balmand, S., Hudcovic, T., Heddi, A., et al. (2016). *Lactobacillus plantarum* strain maintains
1038 growth of infant mice during chronic undernutrition. *Science* 351, 854–857.
- 1039 51. Humphrey, J.H., Mbuya, M.N.N., Ntozini, R., Moulton, L.H., Stoltzfus, R.J., Tavengwa, N.V., Mutasa,
1040 K., Majo, F.D., Mutasa, B., Mangwadu, G., et al. (2019). Independent and combined effects of
1041 improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting
1042 and anaemia in rural Zimbabwe: a cluster-randomised trial. *The Lancet Global Health* 7, e132–
1043 e147.
- 1044 52. Beghini, F., McIver, L.J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A.,
1045 Manghi, P., Scholz, M., Thomas, A.M., et al. (2021). Integrating taxonomic, functional, and strain-
1046 level profiling of diverse microbial communities with bioBakery 3. *Elife* 10, e65088.
- 1047 53. Wieder, C., Frainay, C., Poupin, N., Rodríguez-Mier, P., Vinson, F., Cooke, J., Lai, R.P., Bundy, J.G.,
1048 Jourdan, F., and Ebbels, T. (2021). Pathway analysis in metabolomics: Recommendations for the
1049 use of over-representation analysis. *PLoS Comput Biol* 17, e1009105.
- 1050 54. The Gene Ontology Consortium, Aleksander, S.A., Balhoff, J., Carbon, S., Cherry, J.M., Drabkin, H.J.,
1051 Ebert, D., Feuermann, M., Gaudet, P., Harris, N.L., et al. (2023). The Gene Ontology knowledgebase
1052 in 2023. *Genetics* 224, iyad031.
- 1053 55. Drula, E., Garron, M.-L., Dogan, S., Lombard, V., Henrissat, B., and Terrapon, N. (2022). The
1054 carbohydrate-active enzyme database: functions and literature. *Nucleic Acids Res* 50, D571–D577.
- 1055 56. Saier, M.H., Reddy, V.S., Moreno-Hagelsieb, G., Hendargo, K.J., Zhang, Y., Iddamsetty, V., Lam,
1056 K.J.K., Tian, N., Russum, S., Wang, J., et al. (2021). The Transporter Classification Database (TCDB):
1057 2021 update. *Nucleic Acids Res* 49, D461–D467.
- 1058 57. Caspi, R., Billington, R., Fulcher, C.A., Keseler, I.M., Kothari, A., Krummenacker, M., Latendresse,
1059 M., Midford, P.E., Ong, Q., Ong, W.K., et al. (2018). The MetaCyc database of metabolic pathways
1060 and enzymes. *Nucleic Acids Research* 46, D633–D639.
- 1061 58. Ye, Y., and Doak, T.G. (2009). A parsimony approach to biological pathway
1062 reconstruction/inference for genomes and metagenomes. *PLoS Comput Biol* 5, e1000465.

- 1063 59. Bazanella, M., Maier, T.V., Clavel, T., Lagkouvardos, I., Lucio, M., Maldonado-Gòmez, M.X., Autran,
1064 C., Walter, J., Bode, L., Schmitt-Kopplin, P., et al. (2017). Randomized controlled trial on the impact
1065 of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and
1066 metabolome. *American Journal of Clinical Nutrition* *106*, 1274–1286.
- 1067 60. Davenport, E.R., Cusanovich, D.A., Michelini, K., Barreiro, L.B., Ober, C., and Gilad, Y. (2015).
1068 Genome-wide association studies of the human gut microbiota. *PLoS ONE* *10*.
1069 10.1371/journal.pone.0140301.
- 1070 61. Turpin, W., Bedrani, L., Espin-Garcia, O., Xu, W., Silverberg, M.S., Smith, M.I., Guttman, D.S.,
1071 Griffiths, A., Moayyedi, P., Panaccione, R., et al. (2018). FUT2 genotype and secretory status are
1072 not associated with fecal microbial composition and inferred function in healthy subjects. *Gut*
1073 *Microbes* *9*.
- 1074 62. Bell, A., and Juge, N. (2021). Mucosal glycan degradation of the host by the gut microbiota.
1075 *Glycobiology* *31*, 691–696.
- 1076 63. Colston, J.M., Taniuchi, M., Ahmed, T., Ferdousi, T., Kabir, F., Mduma, E., Nshama, R., Iqbal, N.T.,
1077 Haque, R., Ahmed, T., et al. (2022). Intestinal Colonization With *Bifidobacterium longum*
1078 Subspecies Is Associated With Length at Birth, Exclusive Breastfeeding, and Decreased Risk of
1079 Enteric Virus Infections, but Not With Histo-Blood Group Antigens, Oral Vaccine Response or Later
1080 Growth in Three Birth Cohorts. *Front Pediatr* *10*, 804798.
- 1081 64. Robertson, R.C., Edens, T.J., Carr, L., Mutasa, K., Gough, E.K., Evans, C., Geum, H.M., Baharmand, I.,
1082 Gill, S.K., Ntozini, R., et al. (2023). The gut microbiome and early-life growth in a population with
1083 high prevalence of stunting. *Nat Commun* *14*, 654.
- 1084 65. Stewart, C.J., Ajami, N.J., O'Brien, J.L., Hutchinson, D.S., Smith, D.P., Wong, M.C., Ross, M.C., Lloyd,
1085 R.E., Doddapaneni, H.V., Metcalf, G.A., et al. (2018). Temporal development of the gut microbiome
1086 in early childhood from the TEDDY study. *Nature* *562*, 583–588.
- 1087 66. Yatsunenkov, T., Rey, F.E., Manary, M.J., Trehan, I., Dominguez-Bello, M.G., Contreras, M., Magris,
1088 M., Hidalgo, G., Baldassano, R.N., Anokhin, A.P., et al. (2012). Human gut microbiome viewed
1089 across age and geography. *Nature* *486*, 222–228.
- 1090 67. Marcobal, A., and Sonnenburg, J.L. (2012). Human milk oligosaccharide consumption by intestinal
1091 microbiota: Human milk oligosaccharide consumption. *Clinical Microbiology and Infection* *18*, 12–
1092 15.
- 1093 68. Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H.,
1094 Zhong, H., et al. (2015). Dynamics and stabilization of the human gut microbiome during the first
1095 year of life. *Cell Host and Microbe* *17*, 690–703. 10.1016/j.chom.2015.04.004.
- 1096 69. Collado, M.C., Cernada, M., Bäuerl, C., Vento, M., and Pérez-Martínez, G. (2012). Microbial ecology
1097 and host-microbiota interactions during early life stages. *Gut Microbes* *3*, 352–365.
- 1098 70. Matamoros, S., Gras-Leguen, C., Vacon, F.L., Potel, G., and Cochetiere, M.-F. de L. (2013).
1099 Development of intestinal microbiota in infants and its impact on health. *Trends in Microbiology*
1100 *21*, 167–173.

- 1101 71. Laursen, M.F. (2021). Gut Microbiota Development: Influence of Diet from Infancy to Toddlerhood.
1102 *Annals of Nutrition and Metabolism*.
- 1103 72. Lewis, Z.T., Totten, S.M., Smilowitz, J.T., Popovic, M., Parker, E., Lemay, D.G., Van Tassell, M.L.,
1104 Miller, M.J., Jin, Y.-S., German, J.B., et al. (2015). Maternal fucosyltransferase 2 status affects the
1105 gut bifidobacterial communities of breastfed infants. *Microbiome* 3, 13.
- 1106 73. Ojima, M.N., Jiang, L., Arzamasov, A.A., Yoshida, K., Odamaki, T., Xiao, J., Nakajima, A., Kitaoka, M.,
1107 Hirose, J., Urashima, T., et al. (2022). Priority effects shape the structure of infant-type
1108 *Bifidobacterium* communities on human milk oligosaccharides. *ISME J* 16, 2265–2279.
- 1109 74. Li, M., Zhou, X., Stanton, C., Ross, R.P., Zhao, J., Zhang, H., Yang, B., and Chen, W. (2021).
1110 Comparative Genomics Analyses Reveal the Differences between *B. longum* subsp. *infantis* and *B.*
1111 *longum* subsp. *longum* in Carbohydrate Utilisation, CRISPR-Cas Systems and Bacteriocin Operons.
1112 *Microorganisms* 9, 1713.
- 1113 75. Gotoh, A., Katoh, T., Sakanaka, M., Ling, Y., Yamada, C., Asakuma, S., Urashima, T., Tomabechi, Y.,
1114 Katayama-Ikegami, A., Kurihara, S., et al. (2018). Sharing of human milk oligosaccharides
1115 degradants within bifidobacterial communities in faecal cultures supplemented with
1116 *Bifidobacterium bifidum*. *Scientific Reports* 8, 13958.
- 1117 76. Sakanaka, M., Gotoh, A., Yoshida, K., Odamaki, T., Koguchi, H., Xiao, J.-Z., Kitaoka, M., and
1118 Katayama, T. (2019). Varied Pathways of Infant Gut-Associated *Bifidobacterium* to Assimilate
1119 Human Milk Oligosaccharides: Prevalence of the Gene Set and Its Correlation with *Bifidobacteria*-
1120 Rich Microbiota Formation. *Nutrients* 12, 71. 10.3390/nu12010071.
- 1121 77. Garrido, D., Ruiz-Moyano, S., Lemay, D.G., Sela, D.A., German, J.B., and Mills, D.A. (2015).
1122 Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of
1123 infant gut-associated bifidobacteria. *Sci Rep* 5, 13517.
- 1124 78. Garrido, D., Ruiz-Moyano, S., Kirmiz, N., Davis, J.C., Totten, S.M., Lemay, D.G., Ugalde, J.A.,
1125 German, J.B., Lebrilla, C.B., and Mills, D.A. (2016). A novel gene cluster allows preferential
1126 utilization of fucosylated milk oligosaccharides in *Bifidobacterium longum* subsp. *longum* SC596.
1127 *Sci Rep* 6, 35045.
- 1128 79. Vatanen, T., Ang, Q.Y., Siegwald, L., Sarker, S.A., Le Roy, C.I., Duboux, S., Delannoy-Bruno, O.,
1129 Ngom-Bru, C., Boulangé, C.L., Stražar, M., et al. (2022). A distinct clade of *Bifidobacterium longum*
1130 in the gut of Bangladeshi children thrives during weaning. *Cell* 185, 4280-4297.e12.
- 1131 80. Sela, D.A., Chapman, J., Adeuya, A., Kim, J.H., Chen, F., Whitehead, T.R., Lapidus, A., Rokhsar, D.S.,
1132 Lebrilla, C.B., German, J.B., et al. (2008). The genome sequence of *Bifidobacterium longum* subsp.
1133 *infantis* reveals adaptations for milk utilization within the infant microbiome. *Proceedings of the*
1134 *National Academy of Sciences* 105, 18964–18969.
- 1135 81. Thomson, P., Medina, D.A., and Garrido, D. (2018). Human milk oligosaccharides and infant gut
1136 bifidobacteria: Molecular strategies for their utilization. *Food Microbiology* 75, 37–46.

- 1137 82. LoCascio, R.G., Desai, P., Sela, D.A., Weimer, B., and Mills, D.A. (2010). Broad conservation of milk
1138 utilization genes in *Bifidobacterium longum* subsp. *infantis* as revealed by comparative genomic
1139 hybridization. *Appl Environ Microbiol* 76, 7373–7381.
- 1140 83. Fushinobu, S., and Abou Hachem, M. (2021). Structure and evolution of the bifidobacterial
1141 carbohydrate metabolism proteins and enzymes. *Biochem Soc Trans* 49, 563–578.
- 1142 84. Wei, X., Guo, Y., Shao, C., Sun, Z., Zhurina, D., Liu, D., Liu, W., Zou, D., Jiang, Z., Wang, X., et al.
1143 (2012). Fructose Uptake in *Bifidobacterium longum* NCC2705 Is Mediated by an ATP-binding
1144 Cassette Transporter. *Journal of Biological Chemistry* 287, 357–367. 10.1074/jbc.M111.266213.
- 1145 85. Johnstone, T.C., and Nolan, E.M. (2015). Beyond Iron: Non-Classical Biological Functions of
1146 Bacterial Siderophores. *Dalton Trans* 44, 6320–6339.
- 1147 86. Vazquez-Gutierrez, P., Lacroix, C., Jaeggi, T., Zeder, C., Zimmerman, M.B., and Chassard, C. (2015).
1148 *Bifidobacteria* strains isolated from stools of iron deficient infants can efficiently sequester iron.
1149 *BMC Microbiol* 15, 3.
- 1150 87. Vazquez-Gutierrez, P., de Wouters, T., Werder, J., Chassard, C., and Lacroix, C. (2016). High Iron-
1151 Sequestering *Bifidobacteria* Inhibit Enteropathogen Growth and Adhesion to Intestinal Epithelial
1152 Cells In vitro. *Front Microbiol* 7, 1480.
- 1153 88. Gibson, G. r., and Wang, X. (1994). Regulatory effects of bifidobacteria on the growth of other
1154 colonic bacteria. *Journal of Applied Bacteriology* 77, 412–420.
- 1155 89. Arimond, M., Zeilani, M., Jungjohann, S., Brown, K.H., Ashorn, P., Allen, L.H., and Dewey, K.G.
1156 (2015). Considerations in developing lipid-based nutrient supplements for prevention of
1157 undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS)
1158 Project. *Matern Child Nutr* 11, 31–61.
- 1159 90. Beal, T., White, J.M., Arsenault, J.E., Okronipa, H., Hinnouho, G.-M., Murira, Z., Torlesse, H., and
1160 Garg, A. (2021). Micronutrient gaps during the complementary feeding period in South Asia: A
1161 Comprehensive Nutrient Gap Assessment. *Nutr Rev* 79, 26–34.
- 1162 91. White, J.M., Beal, T., Arsenault, J.E., Okronipa, H., Hinnouho, G.-M., Chimanya, K., Matji, J., and
1163 Garg, A. (2021). Micronutrient gaps during the complementary feeding period in 6 countries in
1164 Eastern and Southern Africa: a Comprehensive Nutrient Gap Assessment. *Nutr Rev* 79, 16–25.
- 1165 92. Park, J.J.H., Harari, O., Siden, E., Dron, L., Zannat, N.-E., Singer, J., Lester, R.T., Thorlund, K., and
1166 Mills, E.J. (2020). Interventions to improve linear growth during complementary feeding period for
1167 children aged 6-24 months living in low- and middle-income countries: a systematic review and
1168 network meta-analysis [version 2; peer review: 3 approved]. 3, 1660.
- 1169 93. Imdad, A., and Bhutta, Z.A. (2011). Effect of preventive zinc supplementation on linear growth in
1170 children under 5 years of age in developing countries: a meta-analysis of studies for input to the
1171 lives saved tool. *BMC Public Health* 11, S22.
- 1172 94. Ashorn, P., Alho, L., Ashorn, U., Cheung, Y.B., Dewey, K.G., Gondwe, A., Harjunmaa, U., Lartey, A.,
1173 Phiri, N., Phiri, T.E., et al. (2015). Supplementation of Maternal Diets during Pregnancy and for 6


- 1174 Months Postpartum and Infant Diets Thereafter with Small-Quantity Lipid-Based Nutrient
1175 Supplements Does Not Promote Child Growth by 18 Months of Age in Rural Malawi: A Randomized
1176 Controlled Trial. *J Nutr* *145*, 1345–1353. 10.3945/jn.114.207225.
- 1177 95. Abellan-Schneyder, I., Matchado, M.S., Reitmeier, S., Sommer, A., Sewald, Z., Baumbach, J., List,
1178 M., and Neuhaus, K. (2021). Primer, Pipelines, Parameters: Issues in 16S rRNA Gene Sequencing.
1179 *mSphere* *6*, e01202-20.
- 1180 96. Paganini, D., Uyoga, M.A., Kortman, G.A.M., Boekhorst, J., Schneeberger, S., Karanja, S., Henet, T.,
1181 and Zimmermann, M.B. (2019). Maternal Human Milk Oligosaccharide Profile Modulates the
1182 Impact of an Intervention with Iron and Galacto-Oligosaccharides in Kenyan Infants. *Nutrients* *11*,
1183 2596.
- 1184 97. Schwartz, D.J., Langdon, A., Sun, X., Langendorf, C., Berthé, F., Grais, R.F., Trehan, I., Isanaka, S.,
1185 and Dantas, G. (2023). Effect of amoxicillin on the gut microbiome of children with severe acute
1186 malnutrition in Madarounfa, Niger: a retrospective metagenomic analysis of a placebo-controlled
1187 trial. *The Lancet Microbe* *4*, e931–e942.
- 1188 98. Ruiz, L., Flórez, A.B., Sánchez, B., Moreno-Muñoz, J.A., Rodríguez-Palmero, M., Jiménez, J., Gavilán,
1189 C.G. de los R., Gueimonde, M., Ruas-Madiedo, P., and Margolles, A. (2020). *Bifidobacterium*
1190 *longum* subsp. *infantis* CECT7210 (*B. infantis* IM-1®) Displays In Vitro Activity against Some
1191 Intestinal Pathogens. *Nutrients* *12*, 3259.
- 1192 99. Henrick, B.M., Rodriguez, L., Lakshminanth, T., Pou, C., Henckel, E., Arzoomand, A., Olin, A., Wang,
1193 J., Mikes, J., Tan, Z., et al. (2021). Bifidobacteria-mediated immune system imprinting early in life.
1194 *Cell* *184*, 3884-3898.e11.
- 1195 100. Dai, D.L.Y., Petersen, C., Hoskinson, C., Del Bel, K.L., Becker, A.B., Moraes, T.J., Mandhane, P.J.,
1196 Finlay, B.B., Simons, E., Kozyrskyj, A.L., et al. (2023). Breastfeeding enrichment of *B. longum* subsp.
1197 *infantis* mitigates the effect of antibiotics on the microbiota and childhood asthma risk. *Med* *4*, 92-
1198 112.e5.
- 1199 101. Barratt, M.J., Nuzhat, S., Ahsan, K., Frese, S.A., Arzamasov, A.A., Sarker, S.A., Islam, M.M., Palit, P.,
1200 Islam, M.R., Hibberd, M.C., et al. (2022). *Bifidobacterium infantis* treatment promotes weight gain
1201 in Bangladeshi infants with severe acute malnutrition. *Sci Transl Med* *14*, eabk1107.
- 1202 102. Nuzhat, S., Hasan, S.M.T., Palit, P., Islam, M.R., Mahfuz, M., Islam, M.M., Alam, M.A., Flannery, R.L.,
1203 Kyle, D.J., Sarker, S.A., et al. (2023). Effects of probiotic and synbiotic supplementation on ponderal
1204 and linear growth in severely malnourished young infants in a randomized clinical trial. *Sci Rep* *13*,
1205 1845.
- 1206 103. Humphrey, J.H., Jones, A.D., Manges, A., Mangwadu, G., Maluccio, J.A., Mbuya, M.N.N., Moulton,
1207 L.H., Ntozini, R., Prendergast, A.J., Stoltzfus, R.J., et al. (2015). The sanitation hygiene infant
1208 nutrition efficacy (SHINE) Trial: Rationale, design, and methods. *Clinical Infectious Diseases* *61*,
1209 S685-702.
- 1210 104. Chasekwa, B., Maluccio, J.A., Ntozini, R., Moulton, L.H., Wu, F., Smith, L.E., Matare, C.R., Stoltzfus,
1211 R.J., Mbuya, M.N.N., Tielsch, J.M., et al. (2018). Measuring wealth in rural communities: Lessons
1212 from the sanitation, hygiene, infant nutrition efficacy (SHINE) trial. *PLoS ONE* *13*, 1–19.

- 1213 105. Maxwell, D., Watkins, B., Wheeler, R., and Collins, G. (2003). The Coping Strategy Index: a tool for
1214 rapid measurement of household food security and the impact of food aid programs in
1215 humanitarian emergencies. (CARE and WFP).
- 1216 106. E.K, G., L.H, M., K, M., R, N., R.J, S., F.D, M., L.E, S., G, P., N, G., M, J., et al. (2020). Effects of
1217 improved water, sanitation, and hygiene and improved complementary feeding on environmental
1218 enteric dysfunction in children in rural Zimbabwe: A cluster-randomized controlled trial. *PLoS*
1219 *Neglected Tropical Diseases* *14*, e0007963.
- 1220 107. Mutasa, K., Ntozini, R., Mbuya, M.N.N., Rukobo, S., Govha, M., Majo, F.D., Tavengwa, N., Smith,
1221 L.E., Caulfield, L., Swann, J.R., et al. (2021). Biomarkers of environmental enteric dysfunction are
1222 not consistently associated with linear growth velocity in rural Zimbabwean infants. *The American*
1223 *journal of clinical nutrition* *113*.
- 1224 108. Colston, J.M., Francois, R., Pisanic, N., Yori, P.P., McCormick, B.J.J., Olortegui, M.P., Gazi, M.A.,
1225 Svensen, E., Ahmed, M.M.M., Mduma, E., et al. (2019). Effects of Child and Maternal Histo-Blood
1226 Group Antigen Status on Symptomatic and Asymptomatic Enteric Infections in Early Childhood.
1227 *Journal of Infectious Diseases* *220*, 151–162.
- 1228 109. Legendre, P., and Anderson, M.J. (1999). Distance-Based Redundancy Analysis: Testing
1229 Multispecies Responses in Multifactorial Ecological Experiments. *Ecological Monographs* *69*, 1–24.
- 1230 110. Anderson, M.J. (2001). A new method for non-parametric multivariate analysis of variance. *Austral*
1231 *Ecology* *26*, 32–46.
- 1232 111. VanderWeele, T.J. (2012). Sample Size and Power Calculations for Additive Interactions. *Epidemiol*
1233 *Methods* *1*, 159–188.
- 1234 112. Naimi, A.I., and Whitcomb, B.W. (2020). Estimating Risk Ratios and Risk Differences Using
1235 Regression. *Am J Epidemiol* *189*, 508–510.
- 1236 113. Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
1237 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B*
1238 *(Methodological)* *57*, 289–300.
- 1239 114. Scholz, M., Ward, D.V., Pasolli, E., Tolio, T., Zolfo, M., Asnicar, F., Truong, D.T., Tett, A., Morrow,
1240 A.L., and Segata, N. (2016). Strain-level microbial epidemiology and population genomics from
1241 shotgun metagenomics. *Nature Methods* *13*, 435–438.
- 1242 115. Murtagh, F., and Legendre, P. (2014). Ward’s Hierarchical Agglomerative Clustering Method:
1243 Which Algorithms Implement Ward’s Criterion? *Journal of Classification* *31*, 274–295.
- 1244 116. Chen, E.Z., and Li, H. (2016). A two-part mixed-effects model for analyzing longitudinal microbiome
1245 compositional data. In *Bioinformatics*, pp. 2611–2617. 10.1093/bioinformatics/btw308.
- 1246 117. Kosmidis, I., Kenne Pagui, E.C., and Sartori, N. (2020). Mean and median bias reduction in
1247 generalized linear models. *Stat Comput* *30*, 43–59.


- 1248 118. Mansournia, M.A., Geroldinger, A., Greenland, S., and Heinze, G. (2018). Separation in Logistic
1249 Regression: Causes, Consequences, and Control. *Am J Epidemiol* 187, 864–870.
- 1250 119. Dixon, P. (2003). VEGAN, a package of R functions for community ecology. *Journal of Vegetation*
1251 *Science* 14, 927–930.
- 1252 120. Stasinopoulos, D.M., and Rigby, R.A. (2007). Generalized additive models for location scale and
1253 shape (GAMLSS) in R. *Journal of Statistical Software* 23, 1–46. 10.18637/jss.v023.i07.
- 1254
- 1255

no IYCF IYCF

A




B





B. longum Rel. Ab. — Low — High

A



B









Table 1. Multivariable regression model¹ to estimate modification of IYCF on stunting at 18mo by mother-infant Lewis-null secretor phenotype discordance among 792 infants in whom mother and infant FUT2 and FUT3 status was ascertained

	<u>Main Effect</u>			<u>Difference-in-Differences for IYCF by FUT2 and FUT3 phenotype combination</u>		
	PD (95%CI)	p-value	Adjusted p-value ²	PD (95%CI)	p-value	Adjusted p-value ²
Both FUT2+/FUT3-	ref	ref	ref	ref	ref	
None FUT2+/FUT3-	0.13(0.01,0.25)	0.041	0.330	-0.21(-0.42,-0.01)	0.039	0.118
Infant only FUT2+/FUT3-	0.15(-0.03,0.33)	0.094	0.277	-0.21(-0.48,0.06)	0.127	0.191
Mom only FUT2+/FUT3-	0.29(0.14,0.44)	0.000	0.007	-0.33(-0.55,-0.10)	0.005	0.015
non-IYCF	ref	ref	ref			
IYCF	0.16(-0.02,0.35)	0.138	0.177			

¹Covariates include season of birth, birthweight, infant sex, ever exclusive breastfeeding at 3mo, age at the 6mo visit, infant WHZ at the 6mo visit, and infant LAZ at the 6mo visit

²Adjusted for multiple hypothesis testing by the Benjamini-Hochberg method
 PD, prevalence difference; 95%CI, 95% confidence interval; ref, referent

Table 2. Multivariable regression models¹ to estimate modification of IYCF on stunting at 18mo by infant gut microbiome species turnover in 53 infants

	PD(95%CI)	p-value	Adjusted p-value ²
PCoA Axis 1		<u>n/N=17/53</u>	
IYCF	-0.51(-0.99,-0.12)	0.009	0.045
PC1	0.21(-0.99,0.45)	0.085	0.204
PC1-by-IYCF ³	-0.76(-0.99,-0.32)	0.001	0.003
PCoA Axis 2		<u>n/N=17/53</u>	
IYCF	-0.14(-0.99,0.12)	0.293	0.469
PC2	-0.06(-0.99,-0.01)	0.020	0.068
PC2-by-IYCF ³	0.14(0.07,0.21)	<0.001	0.001
PCoA Axis 3		<u>n/N=17/53</u>	
IYCF	0.09(-0.99,0.39)	0.543	0.686
PC3	0.04(-0.99,0.09)	0.156	0.340
PC3-by-IYCF ³	-0.08(-0.99,-0.02)	0.016	0.032
PCoA Axis 4		<u>n/N=17/53</u>	
IYCF	0.03(-0.99,0.31)	0.847	0.924
PC4	0.00(-0.99,0.06)	0.994	0.994
PC4-by-IYCF ³	0.03(-0.99,0.12)	0.438	0.501

¹Covariates include birthweight, infant sex, age at the 6mo visit, infant LAZ at the 6mo visit, infant diet diversity score at the 6mo visit, and mother-infant Lewis-null secretor phenotype discordance coded as both, none, infant only or mother only

²Adjusted for multiple hypothesis testing by the Benjamini-Hochberg method

³Differences-in-differences

PD, prevalence difference; 95%CI, 95% confidence interval

Table 3. Multivariable regression models¹ to estimate modification of IYCF on stunting at 18mo by infant gut microbiome species in 53 infants

	PD(95%CI)	p-value	Adjusted p-value ²
Bifidobacterium longum <u>n/N=17/53</u>			
IYCF	-0.16(-0.43,0.10)	0.232	0.976
B.longum	-0.24(-0.43,-0.05)	0.014	0.068
B.longum-by-IYCF ³	0.50(0.26,0.74)	<0.001	<0.001
Bifidobacterium pseudocatenulatum <u>n/N=17/53</u>			
IYCF	-0.54(-1.02,-0.06)	0.029	0.304
B.pseudocatenulatum	1.82(0.48,3.15)	0.008	0.051
B.pseudocatenulatum-by-IYCF ³	-2.00(-3.33,-0.68)	0.003	0.014
Escherichia coli <u>n/N=17/53</u>			
IYCF	0.04(-0.25,0.33)	0.774	1.000
E.coli	0.01(-0.10,0.13)	0.823	0.859
E.coli-by-IYCF ³	-0.07(-0.21,0.08)	0.362	0.592
Dorea longicatena <u>n/N=17/53</u>			
IYCF	0.02(-0.27,0.31)	0.896	1.000
D.longicatena	-0.02(-0.13,0.09)	0.725	0.859
D.longicatena-by-IYCF ³	0.03(-0.39,0.44)	0.898	0.898
Dorea formicigenerans <u>n/N=17/53</u>			
IYCF	-0.18(-0.37,0.01)	0.062	0.324
D.formicigenerans	-0.18(-0.33,-0.03)	0.018	0.073
D.formicigenerans-by-IYCF ³	-0.50(-1.00,-0.00)	0.048	0.145

¹Covariates include birthweight, infant sex, age at the 6mo visit, infant LAZ at the 6mo visit, infant diet diversity score at the 6mo visit, and mother-infant Lewis-null secretor phenotype discordance coded as both, none, infant only or mother only

²Adjusted for multiple hypothesis testing by the Benjamini-Hochberg method

³Differences-in-differences

PD, prevalence difference; 95%CI, 95% confidence interval